 
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  ______________________________________________________________  
 
                                                            
 
Statistical Analysis Plan  
 
 
Cetero Research Protocol No. CTJK09001  
Theracos, Inc. Protocol No. THR -1442 -C-402 
                                      
 
A Phase II, four -week, multi -center, double -blind, placebo -controlled parallel group study 
to evaluate the safety and efficacy of EGT0001442 in subject s with type 2 Diabetes 
Mellitus with an ascending dose safety and pharmacokinetic evaluation period  
 
        
 
Cetero Research  
4520 Dixie Road  
Mississauga, Ontario, L4W 1N2  
Canada  
 
17-May-2010 
Final Version 1.0 
 
                                
 
 
Written By:     
 Jianhua Liu, M.Sc.  
Manager Biostatistics  
Cetero Research  
 
 
  Date  
Approved by:     
 Pina D'Angelo, M.Sc.  
Director Biostatistics  & PK/PD  
Cetero Research  
 
 
 
  Date  
    
 
 Yuan -Di  Halvorsen, Ph.D.  
Clinical  Project  Leader   
Theracos , Inc.  
 
  Date  
 
 
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  ______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17-May-2010                     Page 2 of 100   LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  
AE adverse event  
ANOVA  analysis of variance  
ATC the anatomic therapeutic chemical classification  
AUC  area under the curve  
AUC 0-t area under the plasma concentration -time curve from time 0 to time t 
(time of last quantifiable plasma concentration)  
AUC 0-inf area under the plasma concentration -time curve from time 0 to infinity  
AUC 0-24 area under the plasma concentration -time curve from time 0 to 24 h  
BMI body mass index  
CI confidence interval  
CL/F  the a pparent total body  clearance  
Cmax maximum observed plasma concentration  
CRF case report form  
CV coefficient of variation  
DSMB  data and safety monitoring board  
ECG  electrocardiogram  
FDA food and drug administration  
FPG fasting plasma glucose  
GCP  good clinical practice  
HbA1c  glycated hemoglobin  
ICH international conference on harmonisation  
ITT intent -to-treat 
Kel terminal phase rate constant   
MedDRA  medical dictionary for regulatory activities  
PK pharmacokinetics  
PP per protocol  
SAE serious adverse event  
SAP statistical analysis  plan 
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 3 of 100 SD standard deviation  
SMBG  self monitored blood glucose  
TEAE  treatment emergent adverse event  
Thalf  apparent terminal half life  
Tmax time of  observed  maximum plasma concentration  
UGE0 -24 urinary glucose excretion from 0 to 24 h post dose  
Vz/F the a pparent total volume of distribution  
 
 
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 4 of 100 Table of Contents  
 
List of Abbreviations and Definitions of Terms  ................................ ................................ ........  2 
1. INTRODUCTION  ................................ ................................ ................................ ................  8 
2. OBJECTIVES  ................................ ................................ ................................ .....................  8 
3. OVERALL STUDY  DESIGN AND PLAN  ................................ ................................ ............  9 
4. TREATMENT ADMINISTERED  ................................ ................................ ........................  10 
5. BLINDING  ................................ ................................ ................................ ........................  10 
6. METHOD OF ASS IGNING SUBJECTS TO TREATMENT GROUPS  ...............................  11 
7. SAMPLE SIZE  ................................ ................................ ................................ ..................  11 
8. ANALYSIS POPULATIONS  ................................ ................................ .............................  12 
9. STUDY ENDPOINTS  ................................ ................................ ................................ ....... 13 
10. STATISTICAL METHODS  ................................ ................................ ..............................  13 
10.1 Baseline Characteristics  ................................ ................................ ...............................  14 
10.1.1 Demographics and Baseline Characteristics ................................ ..............................  14 
10.1.2 Medical History  ................................ ................................ ................................ ..........  14 
10.1.3 Inclusion/Exclusion Criteria and Exceptions ................................ ...............................  14 
10.1.4 Urine Drug Screen  ................................ ................................ ................................ ..... 14 
10.2 Primary Analysis  ................................ ................................ ................................ ...........  14 
10.3 Secondary Analyses  ................................ ................................ ................................ ..... 15 
10.4 Safety Analysis  ................................ ................................ ................................ .............  16 
10.4.1 Adverse Event Analysis  ................................ ................................ .............................  16 
10.4.2 Clinical Laboratory Tests  ................................ ................................ ...........................  17 
10.4.3 Concomitant Medication  ................................ ................................ ............................  17 
10.4.4 FPG, Vital Signs, SMBG record, and ECG Parameters  ................................ .............  17 
10.4.5 Physical Exam  ................................ ................................ ................................ ...........  18 
10.5 PK Assessments  ................................ ................................ ................................ ..........  18 
10.6 Exploratory Analysis of the Post -prandial Blood Glucose  ................................ .............  19 
10.7 Interim Analysis  ................................ ................................ ................................ ............  19 
10.8 M issing Data  ................................ ................................ ................................ ................  20 
10.9 Multiple Comparisons  ................................ ................................ ................................ ... 20 
11. TABLE, LISTING AND FIGURE SHELLS  ................................ ................................ ....... 20 
 
Tables:  
 
Table 14.1.1 Disposition of Subjects (Double -blind Segment)  ................................ ..............  22 
Table 14.1.2 Disposition of Subjects  (Dose Escalation Segment)  ................................ .........  23 
Table 14.1.3 Summary of Demographics (Double -blind Segment)  ................................ ....... 24 
Table 14.1.4 Summary of Demographics (Dose Escalation Segment)  ................................ . 26 
Table 14.2.1 Primary Efficacy Analysis: Descriptive Summary of Fasting Plasma Glucose 
from Baseline to End of Treatment Double -blind Segment Intent -to-Treat Analysis Set  28 
Table 14.2.2 Primary Efficacy Analysis: ANCOVA Results on Mean Change in FPG from 
Baseline to End of Treatment Double -blind Segment Intent -to-Treat Analysis Set  ........  29 
Table 14.2.3 Descriptive Summary of Fasting Plasma Glucose from Baseline to End of 
Treatment Double -blind Segment Per -Protocol Analysis Set  ................................ ........  30 
Table 14.2.4 ANCOVA Results on Mean Change in FPG from Baseline to End of 
Treatment  Double -blind Segment Per -Protocol Analysis Set  ................................ ....... 30 
Table 14.2.5 Descriptive Summary of Fasting Plasma Glucose from End of Treatment to 
Post Treatment Double -blind Segment Intent -to-Treat An alysis Set  .............................  31 
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 5 of 100 Table 14.2.6 ANCOVA Results on Mean Change in FPG from End of Treatment to Post 
Treatment Double -blind Segment Inten t-to-Treat Analysis Set  ................................ ..... 32 
Table 14.2.7 Descriptive Summary of Change in Body Weight from Baseline to Day 29 
Double -blind Segment   Intent -to-Treat Analysis Set ................................ ......................  33 
Table 14.2.8 ANCOVA Results on Mean Change in Body Weight from Baseline to Day 29  
Double -blind Segment Intent -to-Treat Analysis Set ................................ .......................  34 
Table 14.2.9 Descriptive Summary of Change in HbA1c from Baseline to Day 29  Double -
blind Segment  Intent -to-Treat Analysis Set  ................................ ................................ .. 35 
Table 14.2.10 ANCOVA Results on Mean Change in HbA1c from Baseline to Day 29 
Double -blind Segment Intent -to-Treat Analysis Set ................................ .......................  36 
Table 14.2.11 Descriptive Summary of Change in 24 h UGE from Baseline to Day 28 
Double -blind Segment  Intent -to-Treat Analysis Set ................................ ......................  37 
Table 14.2.12 ANCOVA Results on Mean Change in 24 h UGE from Baseline to Day 28  
Double-blind Segment Intent -to-Treat Analysis Set ................................ .......................  38 
Table 14.2.13 Summary of Plasma Concentrations of EGT0001442 (ng/mL)   Dose 
Escalation Segment  ................................ ................................ ................................ ...... 39 
Table 14.2.14 Summary of Pharmacokinetic Parameters of EGT0001442  Dose Escalation 
Segment  ................................ ................................ ................................ .......................  40 
Table 14.2.15 Summary of Post Prandial Blood Glucose (mg/dL) in Change from Day 0 to 
Day 2  Dose Escalation Segment  ................................ ................................ .................  41 
Table 14.2.16 Summary of Post Prandial Blood Glucose in AUC  Dose Escalation 
Segment  ................................ ................................ ................................ .......................  42 
Table 14.3.1.1 Summary of TEAEs  Double -blind Segment  Double -blind Safety Analysis 
Set ................................ ................................ ................................ ................................  43 
Table 14.3.1.2 Summary of TEAEs  Dose Escalation Segment  Dose Escalation Safety 
Analysis Set  ................................ ................................ ................................ ..................  44 
Table 14.3.1.3 Summary of TEAEs by System Organ Class, Preferred Term and 
Treatment Group Double -blind Segment   Double -blind Safety Analysis Set  ................  45 
Table 14.3.1.4 Summary of Drug -related TEAEs by System Organ Class, Preferred Term 
and Treatment Group Double -blind Segment   Double -blind Safety Analysis Set  .........  46 
Table 14.3.1.5 Summary of TEAEs Leading to Study Discontinuation by System Organ 
Class, Preferred Term and Treatment Group Double -blind Segment   Double -blind 
Safety Analysis Set  ................................ ................................ ................................ ....... 46 
Table 14.3.1.6 Summary of Serious TEAEs by System Organ Class, Preferred Term and 
Treatment Group Double -blind Segment   Double -blind Safety Analysis Set  ................  46 
Table 14.3.1.7 Summary of TEAEs by System Organ Class, Preferred Term and Dose 
Group Dose Escalation Segment   Dose Escalation  Safety Analysis Set  ......................  47 
Table 14.3.1.8 Summary of Drug -related TEAEs by System Organ Class, Preferred Term 
and Dose Group Dose Esc alation Segment   Dose Escalation Safety Analysis Set  ...... 48 
Table 14.3.1.9 Summary of TEAEs Leading to Study Discontinuation by Syst em Organ 
Class, Preferred Term and Dose Group Dose Escalation Segment   Dose Escalation 
Safety Analysis Set  ................................ ................................ ................................ ....... 48 
Table 14.3.1.10 Su mmary of Serious TEAEs by System Organ Class, Preferred Term and 
Dose Group Dose Escalation Segment   Dose Escalation Safety Analysis Set  .............  48 
Table 14.3.1.11 Summary of TEAEs by Maximum Severity  Double -blind Segment   
Double -blind Safety Analysis Set  ................................ ................................ ..................  49 
Table 14.3.1.12 Summary of TEAEs by Maximum Severity  Dose Escalation Segment   
Dose Escalation Safety Analysis Set  ................................ ................................ ............  50 
Table 14.3 .1.13 Clinical Laboratory Evaluations in Biochemistry (Observed Values)  
Double -blind Segment   Double -blind Safety Analysis Set  ................................ ............  51 
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 6 of 100 Table 14.3.1.14 Clinical Laboratory Evaluations in Change from Baseline in Biochemistry  
Double -blind Segment   Double -blind Safety Analysis Set  ................................ ............  52 
Table 14.3.1.15 Biochemistry Laboratory Shift Table Double -blind Segment   Double -blind 
Safety Analysis Set  ................................ ................................ ................................ ....... 53 
Table 14.3.1.16 Clinical Laboratory Evaluations in Hematology (Observed Values)  
Double -blind Segment   Double -blind Safety Analysis Set  ................................ ............  54 
Table 14.3.1.17 Clinical Laboratory Evaluations in Change from Baseline in Hematology  
Double -blind Segment   Double -blind Safety Analysis Set  ................................ ............  54 
Table 14.3.1.18 Hematology Laboratory Shift Table Double -blind Segment   Double -blind 
Safety Analysis Set  ................................ ................................ ................................ ....... 54 
Table 14.3.1.19 Clinical Laboratory Evaluations in Urinalysis (Observed Values)  Double -
blind Segment   Double -blind Safety Analysis Set  ................................ ........................  54 
Table 14.3.1.20 Clinical Laboratory Evaluations in Change from Baseline in Urinalysis 
Double -blind Segment   Double -blind Safety Analysis Set  ................................ ............  54 
Table 14.3.1.21 Urinalysis Laboratory Shift Table Double -blind Segment   Double -blind 
Safety Analysis Set  ................................ ................................ ................................ ....... 55 
Table 14.3.1.22 Clinical Laboratory Evaluations in Biochemistry (Observed Values)  Dose 
Escalation Segment   Dose Escalation Safety Analysis Set  ................................ ..........  56 
Table 14.3.1.23 Clinical Laboratory Evaluations in Hematology (Observed Values)  Dose 
Escalation Segment   Dose Escalation Safety Analysis Set  ................................ ..........  57 
Table 14.3.1.24 Clinical Laboratory Evaluations in Urinalysis (Observed Values)  Dose 
Escalation Segment   Dose Escalation Safety Analysis Set  ................................ ..........  57 
Table 14.3.1.25 Summary of Vital Signs (Observed Values) Double -blind Segment   
Double -blind Safety Analysis Set  ................................ ................................ ..................  58 
Table 14.3.1.26 Summary of Vital Signs in Change from Baseline  Double -blind Segment   
Double -blind Safety Analysis Set  ................................ ................................ ..................  59 
Table 14.3.1.27 Summary of Vital Signs (Observed Values)  Dose Escalation Segment   
Dose Escalation Safety Analysis Set  ................................ ................................ ............  60 
Table 14.3.1.28 Summary of 12 -Lead ECG (Observed Values)  Double -blind Segment   
Double -blind Safety Analysis Set  ................................ ................................ ..................  61 
Table 14.3.1.29 Summary of 12 -Lead ECG in Change from Baseline  Double -blind 
Segment   Double -blind Safety Analysis Set  ................................ ................................ . 62 
Table 14.3.1.30 Summary of 12 -Lead ECG (Observed Values)  Dose Escalation Segment   
Dose Escalation Safety Analysis Set  ................................ ................................ ............  63 
Table 14.3.1.31 Summary of Fasting Plasma Glucose by Visit (Observed Values)  Double -
blind Segment   Double -blind Safety Analysis Set  ................................ ........................  64 
Table 14.3.1.32 Summary of Concomitant Medication Double -blind Segment   Double -
blind Safety Analysis Set  ................................ ................................ ..............................  65 
Table 14.3.1.33 Summary of Concomitant Medication Dose Escalation Segment   Dose 
Escalation Safety Analysis Set  ................................ ................................ .....................  66 
 
Listings:  
 
Listing 16.2.1 Subject Disposition  ................................ ................................ .........................  68 
Listing 16.2.2 Protocol Deviations  ................................ ................................ ........................  69 
Listing 16.2.3 Subjects Excluded from the Efficacy Analysis (Double -blind Segment)  ..........  70 
Listing 16.2.4.1 Demographics  ................................ ................................ .............................  71 
Listing 16.2.4.2 Medical History  ................................ ................................ ............................  72 
Listing 16.2.4.3 Prior and Concomitant Medication  ................................ ...............................  73 
Listing 16.2.4.4 Inclusion/Exclusion Criteria and Exceptions  ................................ ................  74 
Listing 16.2.4.5 Urine Drug Screen  ................................ ................................ .......................  75 
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 7 of 100 Listing 16.2.5 Study Drug Administration  ................................ ................................ ..............  76 
Listing 16.2.6.1 Fasting Plasma Glucose (mg/dL)  ................................ ................................  77 
Listing 16.2.6.2 Weight  ................................ ................................ ................................ .........  78 
Listing 16.2.6.3 Glycated Hemoglobin A1 (HbA1c) (%)  ................................ ........................  79 
Listing 16.2.6.4 24 h UGE (g/day)  ................................ ................................ ........................  80 
Listing 16.2.6.5 Blood (PK) Sample Collection (Dose Escalation Segment)  .........................  81 
Listing 16.2.6.6 Post Pr andial Blood Glucose (mg/dL) (Dose Escalation Segment)  ..............  82 
Listing 16.2.7.1 Treatment Emergent Adverse Events  ................................ ..........................  83 
Listing 16.2.7.2 Drug -related Treatment Emergent Adverse Events  ................................ ..... 84 
Listing 16.2.7.3 Serious Treatment Emergent Adverse Events  ................................ .............  84 
Listing 16.2.7.4 Treatment Emergent Adverse Events Leading to Study Discontinuation  ..... 84 
Listing 16.2.7.5 Cardiovascular Treatment Emergent Adverse E vents  ................................ . 84 
Listing 16.2.7.6 Pre -treatment Adverse Events  ................................ ................................ ..... 85 
Listing 16.2.7.7 Adverse Events during Washout Period  ................................ ......................  86 
Listing 16.2.8.1  Clinical Laboratory Test Results in Biochemistry  ................................ .........  87 
Listing 16.2.8.2 Clinical Laboratory Test Results in Hematology ................................ ...........  88 
Listing 16.2.8.3 Clinical Laboratory Test Results in Urinalysis  ................................ ..............  88 
Listing 16.2.8.4 Vital Signs  ................................ ................................ ................................ ... 89 
Listing 16.2.8.5 12 -Lead ECG  ................................ ................................ ..............................  90 
Listing 16.2.8.6 Self Monitored Blood Glucose (SMBG)  ................................ .......................  91 
Listing 16.2.8.7 Physical Examination  ................................ ................................ ..................  92 
 
Figures:  
 
Figure 14.2.1 Fasting Plasma Glucose (mean± SE) - Double -blind Segment  .......................  94 
Figure 14.2.2 Fasting Plasma Glucose in Change from Baseline (mean± SE) - Double -
blind Segment  ................................ ................................ ................................ ...............  95 
Figure 14.2.3 Body Weight (mean± SE) - Double -blind Segment  ................................ .........  96 
Figure 14.2.4 Body Weight in Change from Baseline (mean± SE) - Double -blind Segment  .. 96 
Figure 14.2.5 HbA1c (mean± SE) - Double -blind Segment  ................................ ...................  97 
Figure 14.2.6 24h UGE (mean± SE) - Double -blind Segment  ................................ ...............  98 
Figure 14.2.7 Mean Plasma Concentration for EGT0001442 (ng/mL) - Dose Escalation 
Segment  ................................ ................................ ................................ .......................  99 
Figure  14.2.8 Individual Plasma Concentration for EGT0001442 (ng/mL) - Dose Escalation 
Segment  ................................ ................................ ................................ .....................  100 
 
  
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 8 of 100 Statistical Analysis Plan  
1. INTRODUCTION  
This SAP is based on the final Protocol THR-1442 -C-402 Amendment 2 dated 23 
February  2010 . The SAP provides details on the planned statistical methodology for 
analysis of  the study data. The SAP also outlines the statistical programming 
specifications for the tables, listings and figures.   
 
This SAP describes the study endpoints, derived variables, anticipated data 
transformations  and manipulations, and other details of the analyses not provided in the 
study protocol. This SAP therefore outlines in detail all other aspects pertaining to the 
planned analyses and presentations  for this study .  
 
The following documents were reviewed in preparation of this SAP:  
 Clinical Research Protocol final Protocol THR -1442 -C-402 Amendment 1 dated 23 
February  2010  
 Case report forms (CRFs) issued on 22 March  2010: R09 -0980  (THR -1442 -C-402) 
eCRF Template - Insubject  V1.2.pdf and R09 -0980  (THR -1442 -C-402) eCRF 
Template - Outsubject  V1.2.pdf 
 ICH Guidance on Statistical Principles for Clinical Trials.  
 
The reader of th is SAP is encouraged to also read the clinical protocol for details on the 
conduct of this study, and the operational aspects of clinical assessments and timing for 
completing a subject  in this study.  
 
2. OBJECTIVES   
Primary Objective s: 
 
The primary objectives of this study are:  
 
 To determine the effect of EGT0001442 on fasting plasma glucose (FPG) at the 
end of 4 weeks of treatment.  
 To assess the pharmacokinetics and safety and tolerability of EGT0001442 at four 
dose levels in diabetic subjects given the drug daily for 4 weeks.  
 
 
Secondary  Objective s: 
 
 To determine changes in body weight at week 4 from baseline.  
 To determine changes in HbA1c at week 4 compared to baseline.  
 To determine changes in FPG following cessation of treatment  
 To determine the pharmacodynamics of EGT0001442 by urinary glucose excretion 
(UGE) in diabetic subject s on day 0, day 1 and day 28.  
 
PK Objective:  
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 9 of 100  
 To determine the pharmacokinetics of EGT0001442 in diabetic subject s 
 
Exploratory Objective:  
 
 To measure changes in post -prandial blood glucose from baseline to day 2 in the 
20 subject s in the dose escalation segment of the trial while they remain 
supervised in the clinic.  
 
3. OVERALL STUDY DESIGN  AND PLAN  
EGT0001442 is an experimental agent being developed by Theracos Inc. for the treatment 
of type 2 diabetes.  EGT0001442 is a selective inhibitor of human sodium glucose 
cotransporter 2 (SGLT2).  A first -in-human study and a subsequent phase I study in 
diabe tic subject s have previously evaluated the safety and tolerability of EGT0001442 (as 
proline cocrystal) up to a dose of 100 mg/d for 14 days (150 mg/d of cocrystal) in healthy 
volunteers or as a single dose of 100 mg (150 mg of cocrystal) in diabetic subject s. This 
trial is the first to expose human subject s to EGT0001442 as a single agent (i.e., not as 
proline cocrystal) and is conducted at dose levels of 5, 10, 20 and 50 mg per day, or 
placebo, in two segments.  
The first segment is a single center, open labeled pharmacokinetic 3 day in subject  study 
with a 25 day out subject  continuation, intended to assess any significant changes in the 
exposure to EGT0001442 when delivered by single agent crystal compared to proline 
cocrystal. The similar solubility and dissolution rate of the two formulations of EGT0001442 
suggest that significant differences in exposure compared to those observed following 
proline cocrystal administration are unlikely. However a drug and safety monitoring board 
will review the outco mes and pharmacokinetic data to determine if the pharmacokinetic 
profile will result in the mean C max or AUC 0-24 exceeding the NOAEL in male rats (the 
limiting sex and species derived from 28 day repeat dosing studies).  
The second segment of the proposed clinical evaluation is a multicenter, placebo -
controlled, five -arm parallel group, double -blind, randomized clinical trial of 28 day duration 
conducted in an out subject  population. EGT0001442 delivered at dose levels of 5, 10, 20 
and 50 mg per day, or plac ebo, is administered to approximately 25 subject s per dose for 
a period of 28 days followed by a 14 day follow -up period.  
The primary objective of the second segment is to evaluate the efficacy of EGT0001442 in 
the treatment of type 2 diabetes mellitus. A pproximately 125 subjects will be randomly 
assigned to receive EGT0001442 at 5, 10, 20, or 50 mg/day or placebo with an equal 
number of subjects per group.  
The primary efficacy end point is the assessment of the effect of EGT0001442 on fasting 
plasma gluco se (FPG) after 4 weeks on treatment compared to baseline FPG values. The 
secondary efficacy end points include:  
 
•   Changes in body weight at week 4 from baseline  
•   Changes in HbA1c at week 4 compared to baseline  
•   Change in FPG following cessation of treatment  
•   Pharmacodynamic effects of EGT0001442 on urinary glucose excretion (UGE) in    
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 10 of 100     diabetic subjects on day 0 (baseline), day 1 and day 28.  
 
Safety of EGT0001442 will be evaluated by assessment of advers e events and 
concomitant medication records, hematology and blood chemistry laboratory results, 
cardiovascular events, electrocardiograms (ECG), urine electrolytes and urinalysis.  
PK parameters will be evaluated in the 20 subjects in the dose escalation se gment. An 
exploratory analysis of changes in post -prandial blood glucose on day 0 and day 2 while 
in-clinic from subjects in the dose escalation segment will also be conducted.  
4. TREATMENT ADMINISTERED  
In the open labeled, dose escalation segment, subject s will take one of the 5 mg, one of 
the 10 mg, two of the 10 mg, or two of the 25 mg EGT0001442 capsules daily in the 5, 10, 
20, or 50 mg cohort.  
In the out subject  randomization segment, the following treatments will be administered:  
Table  1.  EGT0001442  or placebo treatments   
Treatment group  Placebo  
capsule /day  EGT0001442  
capsules /d ay Total # 
capsules/day  5 10 25 
5 mg EGT0001442  1 1 -- -- 2 
10 mg EGT0001442  1 -- 1 -- 2 
20 mg EGT0001442  -- -- 2 -- 2 
50 mg EGT0001442  -- -- -- 2 2 
Placebo  2 -- -- -- 2 
 
During the dose escalation segment of the study, the study drug will be administered orally 
to subject s in the upright position with approximately 200 mL of water between 07:00 h 
and 10:00 h, following a minimum of  a 10 h overnight fast.  During fasting, no fluids will be 
taken in the two hours prior to drug administration.  The capsules will be swallowed without 
chewing. Breakfast will be given 0.5 h after dosing.  Administration of all study medications 
will be su pervised.  After drug administration, a hand and mouth inspection will take place.  
In the out subject  setting, subject s will be instructed to self administer one capsule from 
each of the two bottles prior to breakfast once daily for 25 or 28 days, respectiv ely, and 
complete the dosing log.  Taking the study medication with a glass of water is 
recommended.  
5. BLINDING  
The dose escalation segment of the study will be open labeled.  In the randomization 
segment, the study drug will be blinded to the sponsor, investigators, the study 
coordinator, study subject s, and pharmacist.  Upon randomization, each subject  will 
receiv e a subject  randomization number and a drug kit number assigned to the subject .  
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 11 of 100 The dosing information will remain blinded to all of the study team until the last subject  has 
completed the last follow up visit  and the database has been locked . A designate d 
statistician that will provide safety data upon request from the DSMB will be allowed to 
receive unblinded data.  
To manage the safety monitoring and maintain blinding of the treatment, there will be an 
unblinded study staff who will review the FPG data a nd alert the investigator  and essential 
study staff if glucose is below 2.8 mmol/L (50 mg/dL), 3.9 mmol/L (70 mg/dL), or above 12 
mmol/L (216 mg/dL), 15 mmol/L (270 mg/dL) or 16.7 mmol/L (300 mg/dL). The actual 
numerical values of the FPG will remain blind ed to all study personnel and subject s unless 
clinically indicated, as outlined in section 5.4.  
The investigator will also receive a sealed envelope for each subject  containing a 
description of the dispensed medication.  The envelope can be opened only if  knowledge 
of the test substance is needed to manage the subject ’s condition.  If opened, the date of 
opening and the reason for opening must be written on the envelope. At the conclusion of 
the study, all envelopes must be returned to the Sponsor. These w ill be checked to ensure 
that the seals had not been broken, unless warranted by the occurrence of the events 
mentioned above.  If unblinding occurs, the time and reason for unblinding will be recorded 
on the CRF and the sponsor must be notified within 24 h. 
6. METHOD OF ASSIGNING SUBJECT S TO TREATMENT GROUPS  
The dose escalation segment of the study will be open labeled. Study drug will be provided 
to the site pharmacist in bottles of 30 capsules. The pharmacist will dispense the study 
drug to the subject s.  
In the randomization segment, eligible subject s who complete the 1 5 ± 2 day washout 
period to verify eligibility for the study and stability of their diabetes will be randomized to 
receive EGT0001442 or placebo according to a randomization code generated  by the 
Pharmacometric Department of the contract research organization (CRO). Approximately 
125 subject s will be randomly assigned to a treatment group within each treatment center 
to control for any potential bias due to center. Subject s are assigned to placebo or 
EGT0001442 at doses of 5, 10, 20, or 50 mg/day in a 1:1:1:1:1 ratio. Randomization will 
be stratified by study center. Completion of a block of 5 will initiate the assignment of a 
new random block and the process will continue until all subject s are enrolled. This 
randomization protocol is designed to balance experimental treatments within each center.  
The Outsubject  Segment  of this study will be conducted at multiple investigative sites and 
will likely involve variable numbers of subject s at each site. Enrollment will be on a 
competitive basis but will be capped at 40% of the total randomized subject s (50 subject s) 
from one center.  
7. SAMPLE SIZE  
The efficacy pairwise null and alternative hypotheses to be assessed are as follows:  
H0i: μi = μ P 
vs. 
H1i: μi ≠ μ P 
 
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 12 of 100 where  μi = the mean change in FPG from baseline to week 4  for dose i (i = 5, 10, 20 or 50 
mg/day of EGT0001442) and  μP = the mean change in FPG from baseline to week 4  for 
placebo.  The test of each pairwise null hypothesis will be carried out at the two -sided 0.05 
level of significance; no adjustment for multiple comparisons will be made.  
 
The sample size of 25 subject s per group was calculated based on the following 
assumptions:  
1. Baseline mean (± standard deviation) FPG is 190 (± 40) mg/dL for each dose 
group;  
2. The active doses will decrease FPG on average by 25 (± 25 ) mg/dL from baseline 
to day 28  
3. The placebo will not experience a substantive average decrease in mean F PG from 
baseline to day 28; the standard deviation of the change in mean FPG from 
baseline to day 28 is assumed conservatively to be 25 (same standard deviation as 
for active doses).  
4. The two -sided significance level for each pairwise hypothesis is 0.05.  
 
Under the above assumptions, an evaluable sample size of 22 evaluable subject s per 
treatment arm yields approximately 90% power that at least one dose will be found to be 
significantly different from placebo.  A sample size of 25 subject s per treatment arm  will be 
enrolled to account for any subject  lost-to-follow -up. 
8. ANALYSIS POPULATION S 
Intent -to-Treat Analysis Set:    
All randomized subjects in segment 2 of the study .  This is the analysis set on which 
efficacy endpoints will be evaluated.  All subject s will be analyzed according to the 
treatment to which they were randomized.  The Intent -to-Treat Analysis Set will be used to 
perform the efficacy analysis for the double -blind segment  only.   
 
Per-Protocol Analysis Set:   
The subset of subject s from the Int ent-to-Treat analysis set that received at least 24 doses 
of study drug  to which they were randomized , did not miss more than one dose in the last 
week of study medication, did not have any major protocol deviations and were measured 
for FPG visit with confirmed ≥10 hour fast at the  day 27 and day 29 visits within the 
specified visit window.  Subject s who stopped treatment due to rescue medication are also 
included in the analysis set.  All subject s will be analyzed according to the treatment 
received . 
The Per-Protocol Analysis Set will be evaluated only for primary efficacy to confirm results 
from the Intent -to-Treat Analysis Set. The final subject  evaluability will be performed prior 
to breaking treatment codes and locking the database.  
Double -blind Safet y Analysis Set:   
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 13 of 100 All randomized subject s who receive at least one dose of treatment during the 
randomization segment.  Subject s will be analyzed according to the treatment received.  
The Double -blind Safety Analysis Set will be used to perform  safety assessment s for the 
double -blind segment . 
Dose -Escalation Safety Analysis Set:    
All subject s who receive at least one dose of treatment during the dose escalation 
segment of the study. Subject s will be analyzed according to the treatment received.   
The Dose -Escalation Safety Analysis Set will be used to perform safety assessment s for 
the open -label dose escalation segment .  
9. STUDY ENDPOINTS  
Primary Efficacy Endpoint  
The primary efficacy endpoint is change in FPG.   
Secondary Efficacy Endpoints  
 Change in body weight from baseline to day 29  
 Change in HbA1c from baseline to day 29.  
 Change in FPG from cessation of treatment (days 27/29 to days 41/43).  
 24 h UGE on day 0, day 1 and day 28  
Primary Safety Endpoints  
 Adverse events  
 Clinical  and laboratory variables  
 Concomitant medication   
 FPG, Vital signs , SMBG record, and ECG parameters   
 
10. STATISTICAL METHODS  
Data will be summarized  with respect to demographic and baseline characteristics, 
efficacy variables and safety variables.  
Summary statistics will include the mean, N, standard deviation, median, minimum, and 
maximum values for continuous variables, and frequencies and percentages for 
categorical variables.  
If not otherwise specified, all statistical analyses will be two -sided and the Type I (alpha) 
error is fixed at the 5% level.  
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 14 of 100 10.1 Baseline Characteristics  
10.1.1 Demographics  and Baseline Characteristics  
Baseline characteristics will be descriptively summarized for all subject s by treatment 
group for the ITT population i n the Double -blind Segment , and for all subject s in the dose 
escalation segment by dose.  Continuous measures will be summarized with sample size, 
mean, median, standard deviation, minimum and maximum; categorical measures will be 
presented with the counts  and percents of subject s in each category.  No statistical tests 
comparing treatments at baseline will be performed.   
Age is  calculated in years after rounding down as follows:  
Year of age = (Date inform ed consent signed  - Date of birth ) / 365.25  
All data will be listed  by study seg ment, treatment  group  and subject  in the double -blind 
segment and by study segment, dose and subject  in the dose escalation segment.  
10.1.2 Medical History  
Medical history data recorded at screening will be listed by study segment, treatment 
group and subject  in the double -blind segment  and by study segment, dose and subject  in 
the dose escalation segment.  
10.1. 3 Inclusion/ Exclusion  Criteria and Exceptions  
Subject  inclusion/exclusion criteria and exceptions will be listed by  study segment, 
treatment group and subject  in the double -blind segment and by study segment, dose and 
subject  in the dose escalation segment.  
10.1. 4 Urine Drug Screen  
Urine drug screen will be listed by study segment, treatment group and subject  in the 
double -blind segment and by study segment, dose and subject  in the dose escalation 
segment.  
10.1.5 Study Drug Administration  
Visit, date and  time for study drug administration will be listed by study segment, treatment 
group and subject  in the double -blind  segment and by study segment, dose and subject  in 
the dose escalation segment.  
10.2 Primary Analys is 
Efficacy analysis will only be performed for the double -blind randomization  segment.  FPG 
from subjects in segment 1 will be presented in by -subject listings.  
Response Variable and Baseline : 
The primary efficacy endpoint of change in FPG  will be treated as the response 
variable . FPG will be determined from the blood samples drawn at baseline, defined as 
the mean of FPG values on day -2 and day 1 and af ter 4 weeks of treatment, defined 
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 15 of 100 as the mean of FPG values on day 27 and day 29. If one of the two FPG values at 
baseline or at 4 -week treatment is missing, the single value available will be used.  If 
both values are missing (either baseline or at the 4 -week treatment), this data will not 
be used.  
Descriptive Summary:  
Descriptive statistics (sample size, mean, median, standard deviation, minimum and 
maximum) of the primary endpoint will be presented for each treatment group.  In 
addition, descriptive statis tics of the baseline and after 4 weeks of treatment values will 
be presented.  
ANCOVA Model:  
Pairwise comparisons of each active dose versus placebo on mean change in FPG 
from baseline will be carried out at the two -sided 0.05 alpha level of significance us ing 
analysis of covariance adjusting for study center and baseline FPG. Baseline FPG and 
center will be treated as covariate. The pairwise differences in mean change in FPG 
means between each dose and placebo, and its associated two -sided 95% confidence 
interval, adjusted for study center and baseline FPG will be presented.  
Assessment  of Interactions:  
The interactions of treatme nt-by-baseline and treatment -by-center will be assessed in 
two separate models  using 2 two-way analysis of covariance model s with the effects of 
treatment, center  and baseline FPG  common to both .  
A non -significant interaction effect at the 0.10 level of s ignificance or a significant 
interaction that is only quantitative and not qualitative in nature (i.e. where the 
treatment effect differs only in magnitude but not direction across study centers) will 
support the pooling of subject s across study centers fo r purposes of the primary 
analysis pairwise comparisons. Centers with less than 5 subjects  randomized  will be 
pooled into one or more centers based on the geographic regions .  
Missing Data:  
No imputation will be carried out for missing data with the exception of subject s who 
ended treatment due to rescue medication. For such subject s, the last FPG value 
measured prior to the subject  receiving rescue medication will be carried forward to 
day 2 9.  
10.3 Secondary  Analyse s 
Analysis for the secondary endpoints will be carried out in a similar manner as for the 
primary efficacy endpoint of FPG. The change in FPG following cessation of treatment 
will be determined from the blood samples drawn at week  4 of treatment, defined as 
the mean of FPG values on day 27 and day 29 to week 6, defined as the mean of FPG 
values on day 41 and day 43. No imputation will be carried out for missing data. Due to 
the secondary nature of these outcomes, no assessments of the treatment -by-center 
interaction will be carried out, unless  a significant qualitative treatment -by-center 
interaction is found for FPG. The interaction of treatment -by-baseline, however, will be 
carried out on all secondary analyses where baseline is m easured.  
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 16 of 100 Baseline for weight is defined as the pre -dose weight value on Day 1 at Visit 5. 
Baseline for HbA1c is defined as the pre -dose  HbA1c value on Day 1 at Visit 5. 
Baseline for 24h UGE is defined as the pre -dose UGE value on Day 0 at Visit 4.  
If the safety and ITT analysis sets  differ by more than 10%, the analysis on UGE will 
also be conducted on the safety analysis set . 
10.4 Safety Analysis  
Safety endpoints will be summarized using descriptive statistics and by -subject  listings 
included in the clinical study report. Safety analysis will be performed separately for 
subject s in the double -blind study and subject s in the dose escalation study where 
applicable. Results will be presented by treatment group/dose group.  
For repeat safety assessments  (clinical laboratory tests , vital signs and ECGs),  the 
following will apply for the summary tables.   
 Repeat safety assessments prior to dosing, the repeated values will be used for 
calculations but all values will be included in the listings.  
 Repeat safety  assessments after dosing, the original values will be used but all values 
will be included in the listings.   
10.4.1 Adverse Event Analysis  
Adverse events will be mapped  using the Medical Dictionary for Regulatory Activities 
(MedDRA) central coding dictionary  (version  12.1).  Each adverse event is to be evaluated 
for date/time of onset, duration, severity  and causal relationship with the study drug or 
other factors.   
Treatment Emergent Adverse Events  
Treatment Emergent A dverse Events (TEAEs) are any AEs that start or worsen at or 
after administration of the first dose of study medication.  
Adverse Event listings will be provided for all TEAEs, all drug -related TEAEs, serious 
TEAEs, and any TEAEs leading to study discontinuation.  
The number and percentage of subject s experiencing TEAEs will be summarized by 
treatment group overall and for each System Organ Class and Preferred Term. Each 
subject  will be counted only once within each preferred term. If the same AE occurs in 
a subject  on multiple occasions, the highest severity and least complementary 
relationship will be assumed. If two or more AEs are reported as a single event, the 
individual terms will be reported as separate AEs.  
This analysis will be repeated for drug -related an d serious TEAEs and for TEAEs 
leading to study discontinuation.  
TEAEs will also be tabulated by maximum severity experienced.  
No formal statistical tests comparing treatment groups will be performed.  
Adverse Events  during Washout Period  
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 17 of 100 Adverse events reported during the washout period will be presented by subject -
listing s. 
Serious Adverse Events  
Serious adverse events will be listed by -subject listing s. 
Cardiovascular Risk Assessment  
Cardiovascular  adverse events will be presented in by -subject listing s. 
10.4.2 Clinical Laboratory Tests 
Clinical laboratory tests include clinical chemistries, CBC with differential, urinalysis, and 
urinary electrolytes. These variables will be presented in by -subject  listings  by study 
segment, treatment /dose  group and subject . 
Descriptive statistics (sample size, mean, median standard deviation, minimum, and 
maximum) of the continuous variables at each visit will be summarized for both 
double -blind segment and dose escalation segment by treatment/dose group.  
Change from  baseline to each visit will be presented  for double -blind segment . 
Baseline is defined as the laboratory value prior to dosing. A paired t -test assessing 
the significance of the change from baseline will be presented for each variable within 
each treatmen t group.   
Shift tables displaying the change in normality status from baseline to post -baseline 
visits will be presented  for the double -blind segment .  
10.4.3 Concomitant Medication  
Concomitant medications will be coded using the World Health Organization Dictionary 
(WHOD rug Version 101E).  A table of concomitant medications based on the anatomic 
therapeutic chemical classification (ATC) and preferred name will be produced  by 
treatment/dose group .  
A listing of concomitant medications will include all medica tions taken during the 
course of the study.  
Any medications taken prior to the start of the study medication will be listed and 
summarized in a similar manner.  
No formal statistical tests comparing treatment groups will be performed.  
10.4.4 FPG, Vital Signs, SMBG record, and ECG Parameters  
Vitals signs including pulse, systolic and diastolic blood pressure at sitting position, 
respiration rate, and temperature will be measured at screening, prior to dosin g, and at 
each follow up visit. 
A 12 -lead electrocardiogram (ECG) will be conducted at screening, prior to dosing, 
and at each follow up visit.  
Fasting plasma glucose, vital signs and ECG parameters will be listed and presented 
in a similar manner as for clinical laboratory tests  above.   
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 18 of 100 The SMBG record will be summarized in by -subject  listings.  
10.4.5 Physical Exam  
A complete physical examination will be performed at screening and at the termination 
visit. A complete physical examination will include measurement of body weight and heig ht 
(height will be measured only at screening), general assessment of all body systems 
(except genitals) including the skin, head, eyes, ears, nose, throat, neck, thyroid, lungs, 
heart, abdomen, lymph nodes, and extremities. A partial physical examination will include 
body weight and general assessment of the skin, heart, lungs and abdomen.  
Physical exam will be listed by study segment, treatment group and subject  in the double -
blind segment and by study segment, dose and subject  in the dose escalation segment.  
10.5 PK Assessments  
Pharmacokinetic analyses will be performed for EGT0001442  plasma data.   All subjects 
who received  EGT0001442  and have sufficient plasma concentration data will be included 
in the analysis to characterize the PK of EGT0001442 . This determination will be made by 
the study pharmacokineticist.  
 
Subjects who experience emesis will be treated according to Cetero Resea rch SOP 
entitled “Handling Subjects Experiencing Emesis Episode(s) in BA/BE Studies.”  Although 
the SOP's scope is specified as for BA/BE studies, it will be adopted for the analysis of this 
study, where applicable.  Subjects vomiting within 6.6 hours after  drug administration will 
be dropped from the study (based on 2 times the a priori mean population Tmax of 3.3 
hours). Their samples will be analyzed by the bioanalytical laboratory and presented in the 
report but will be excluded from the pharmacokinetic analyses . 
 
Concentration v alues below the lower limit of quantification (BL Q) will be treated according 
to Cetero Research SOP entitled  “Handling BLQ data in PK/PD studies”.  Subjects with 
BLQ values between two non -BLQ concentrations will be set to missing.   BLQ values that 
occur at the beginning on the profile will be set to zero.  
 
Data from subjects with missing concentration values (missed blood draws, lost samples, 
samples unable to be quantitated) may be used if pharmacokinetic parameters can b e 
estimated using the remaining data points. Otherwise, concentration data from these 
subjects will be excluded from the final analysis.  
 
A non -compartmental pharmacokinetic analysis (SAS, Cary, NC or WinNonlin 5.0.1, 
Pharsight Corp., Mountain View, CA, US A) will be used to calculate the PK parameters for 
each subject . The actual time of sample collection will be used in the PK parameters 
calculations . 
 
 Cmax Maximum observed plasma concentration  
 Tmax Time of observed  maximum plasma concentration  
 Kel        Terminal phase rate constant  
 Thalf        Apparent terminal half life  
 CL/F  The apparent total body clearance  
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 19 of 100  Vz/F The apparent total volume of distribution  
 AUC 0-t  Area under the plasma concentration -time curve from Time 0 to Time t  
 (time of last quanti fiable plasma concentration)  
 AUC 0-inf  Area under the plasma concentration -time curve from Time 0 to infinity  
 AUC 0-24  Area under the plasma concentration -time curve from Time 0 to 24 h  
 
Descriptive statistics ( arithmetic mean, standard deviation [sd], median, minimum , 
maximum , coefficient of variation ) will be summarized by dose group  for the parameters 
listed above and for ln -AUC 0-t, ln-AUC 0-24, ln-AUC 0-inf and ln -Cmax. Additionally, geometric 
means will be calculated for AUC 0-t, AUC 0-24, AUC 0-inf and C max.  
No value of Kel, AUC 0-inf, Thalf,  CL/F , or Vz/F will be reported for cases that do not exhibit 
a terminal log -linear phase in the concentration versus time profile.  
 
Other pharmacokinetic parameters may be calculated if deemed necessary.  
10.6 Exploratory Analysis of the Post-prandial Blood Glucose  
The impact of EGT0001442  on 2 -h post -prandial glucose levels will be determined by 
measuring fingerstick blood glucose values at 7 points on day 0  and then again on day 2 
of drug administration for th e 20 subject s in the dose escalation phase of the trial.  
Measurements will be taken before each meal (breakfast, lunch, and dinner) and then 2 
hour after meal completion. A seventh measurement will be taken at 10 pm (
 30 mins) at 
night.  
The difference between the post -meal measurement and the measurement before the 
same meal will be identified as the post -prandial glucose change for that meal.    For each 
meal, the difference in day 0 to day 2 post -prandial glucose changes  will be descript ively 
summarized for all subject s in the dose escalation segment, categorized by dose.   The 
data will be summarized with sample size, mean, median, standard deviation, minimum 
and maximum.   No statistical tests comparing doses will be performed  
For each subject , AUC of the glucose levels across the 7 points will be calculated at each 
of day 0 and day 2.   The difference in day 0 to day 2 AUC will be descriptively summarized 
for all subject s in the dose escalation segment, categorized by dose.   The data will be 
summarized with sample size, mean, median, standard deviation, minimum and 
maximum.   No statistical tests comparing doses will be performed.  
10.7 Interim Analysis  
There will be no formal interim efficacy analysis for this study.  An independent data and  
safety monitoring board (DSMB) will inspect the safety data from the dose escalation 
segment, review SAE reports, and will periodically inspect unblinded safety data from the 
double -blind study.  A DSMB charter will be written outlining the safety data to  be 
inspected periodically by the DSMB.  
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 20 of 100 10.8 Missing Data  
No imputation will be carried out for missing data with the exception of subject s who ended 
treatment due to rescue medication.  For such subject s, the last FPG value measured prior 
to the subject  receiving rescue medication will be carried forward to Day 28.  
10.9 Multiple Comparisons  
Given the Phase II nature of this study, n o adjustment  of the significance level  for multiple 
comparisons will be made . 
11. TABLE, LISTING AND FIGURE SHELLS  
The following shells are provided in order to provide a framework for the display of data 
from this study. The shells may change due to unforeseen circumstances. These shells 
may not be reflective of every aspect of this study but are intended to show the general 
layout of the Table s, Listings and Figures that will be included in the final report. Tables 
and listings are numbered following the ICH structure. Table headers, variables names 
and footnotes will be modified as needed following data analyses. Ple ase note that all 
summary tables  and listings  will be generated using SAS® Version 9.1.3.  Figures w ill be 
generated using SigmaPlot Version 10  and/or SAS® Version 9.1.3 . 
 
 
  
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  _______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 21 of 100  
 
 
 
 
 
Summary Tables  
 
 
 
 
 
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 22 of 100  
Table 14.1.1 Disposition of Subject s (Double -blind Segment ) 
     
 
_____________________________________________________________________________________________________________________________ _____________  
 
                                                    Treatment Group   
                ______________________________________________ ______________________   
       
           EGT0001442      EGT0001442   EGT0001442     EGT0001442  
        Placebo  5 mg           10 mg   20 mg  50 mg         Overall           
         (N=xx)        (N=xx)         (N=xx)   (N=xx)        (N=xx)         (N=xx)                                 
____________________________________________________________________________________________________________ _______________________________  
 
Number of subjects randomized (N)    xx  xx             xx     xx      xx        xx      
Included in Double-blind Safety Analysis Set  [n (%)] xx(xx.x%)      xx(xx.x%)       xx(xx.x%)   xx(xx.x%)   xx(xx.x%)   xx(xx.x%)  
Included  in Intent -to-Treat Analysis Set  [n (%)] xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)  xx(xx.x%)   xx(xx.x%)  
Included  in Per-Protocol Analysis Set  [n (%)]  xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)  xx(xx.x%)   xx(xx.x%)  
Included in Completed study [n (%)]             xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)   xx(xx.x%)  xx(xx.x%)                                            
Discontinued from study [n (%)]                  xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)    xx(xx.x%)    xx(xx.x%)                                          
Reason for Discontinuation                      
   Discontinued due to Adverse Event [n ( %)]       xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)    xx(xx.x%)   xx(xx.x%)                                             
   Subject elected to withdraw from stud y [n (%)]       xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)     xx(xx.x%)   xx(xx.x%)                                          
 Death [n (%)]                    xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)     xx(xx.x%)   xx(xx.x%)                                         
 Study terminated by sponsor [n (%)]                 xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)     xx(xx.x%)   xx(xx.x%)                                          
  Investigator decision [n (%)]                        xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)    xx(xx.x%)   xx(xx.x%)                                           
   Lost to follow -up [n (%)]                      xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)    xx(xx.x%)   xx(xx.x%) 
 Poor Glycemic Control [n (%)]                      xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)    xx(xx.x%)  xx(xx.x%)                                       
 Other [n (%)]                                  xx(xx.x%)      xx(xx.x%)      xx(xx.x%)   xx(xx.x%)    xx(xx.x%)   xx(xx.x%)                                
_____________________________________________________________________________________________________________________________ ______________  
N: Number of subjects randomized  in the s pecified treatment group 
n: Number of subjects                      
%: Percentage based on N  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 23 of 100 Table 14.1. 2 Disposition of Subject s (Dose Escalation S egment)  
     
 
_____________________________________________________________________________________________________________________________ _____________  
                                      
                    Dose Group  
         _________________________________________ __________________________ ______  
      
         EGT0001442         EGT0001442   EGT0001442    EGT0001442  
        5 mg           10 mg  20 mg           50 mg        Overall              
         (N=xx)            (N=xx)  (N=xx)    (N=xx)    (N=xx)                                   
______________________________________________________________________________________________________________ ____________________________  
 
Number of subjects enrolled (N)     xx     xx              xx     xx            xx        
Included in Dose -Escalation Safety Analysis Set  [n (%)] xx(xx.x%)         xx(xx.x%)       xx(xx.x%)   xx(xx.x%)    xx(xx.x%)  
Included in Completed study [n (%)]             xx(xx.x%)         xx(xx.x%)       xx(xx.x%)    xx(xx.x%)     xx(xx.x%)                                             
Discontinued from study [n (%)]                  xx(xx.x%)         xx(xx.x%)       xx(xx.x%)    xx(xx.x%)     xx(xx.x%)                                             
Reason for Discontinuation                      
   Discontinued due to Adverse Event [n (%)]       xx(xx.x%)         xx(xx.x%)       xx(xx.x%)    xx(xx.x%)    xx(xx.x%)                                                
   Subject elected to withdraw from study [n (%)]       xx(xx.x%)         xx(xx.x%)       xx(xx.x%)    xx(xx.x%)    xx(xx.x%)                                              
 Death [n (%)]                    xx(xx.x%)         xx(xx.x%)       xx(xx.x%)    xx(xx.x%)    xx(xx.x%)                                              
 Study terminated by sponsor [n (%)]                 xx(xx.x%)         xx(xx.x%)       xx(xx.x%)    xx(xx.x%)    xx(xx.x%)                                              
  Investigator decision  [n (%)]                       xx(xx.x%)         xx(xx.x%)       xx(xx.x%)    xx(xx.x%)    xx(xx.x%)                                              
   Lost to follow -up [n (%)]                      xx(xx.x%)         xx(xx.x%)       xx(xx.x%)    xx(xx.x%)     xx(xx.x%)                                             
 Other [n (%)]                                  xx(xx.x%)         xx(xx.x%)       xx(xx.x%)    xx(xx.x%)     xx(xx.x%)                                       
   
______________________________________________________ _________________________________________________________ __________________________  
N: Number of subjects enrolled  in the specified  dose group 
n: Number of subjects                      
%: Percentage based on N 
 
(Source: path \program name  Date /time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 24 of 100 Table 14.1. 3 Summary of Demographics  (Double -blind Segment ) 
     
 
___________________________________________________________________________________________ _________________ ____________________  
                                      
                 Treatment Group   
             _______________________________________________________________ ______________    
       
              EGT0001442       EGT0001442  EGT0001442     EGT0001442  
      Placebo        5 mg           10 mg  20 mg       50 mg          Overall           
Parameter    Statistic  (N=xx)       (N=xx)        (N=xx) (N=xx)         (N=xx)     (N=xx)                                
_______________________ _____________________________________________________________________________________ _____________________  
 
Age (years)   n              xx             xx             xx                xx         xx       xx                     
                        Mean ± SD xx ± x.x  xx ± x.x   xx ± x.x   xx ± x.x    xx ± x.x   xx ± x.x  
                        Median         xx             xx             xx                xx         xx       xx                     
    Min , Max      xx , xx  xx , xx  xx , xx  xx , xx   xx , xx  xx , xx 
                                                                                                                                                  
Height (cm)               n  xx             xx             xx                xx   xx         xx                   
                        Mean ± SD  xx.x ± x.xx  xx.x ± x.xx  xx.x ± x.xx  xx.x ± x.xx  xx.x ± x.xx   xx.x ± x.xx  
                        Median         xx.x    xx.x   xx.x  xx.x   xx.x   xx.x 
    Min , Max      xx.x , xx.x  xx.x , xx.x  xx.x , xx.x xx.x , xx.x  xx.x , xx.x  xx.x , xx.x  
                                                                                                                                                  
Weight (kg)             n  xx             xx             xx                xx   xx        xx                    
                        Mean ± SD  xx.x ± x.xx  xx.x ± x.xx  xx.x ± x.xx  xx.x ± x.xx  xx.x ± x.xx   xx.x ± x.xx  
                        Median         xx.x   xx.x   xx.x  xx.x   xx.x   xx.x 
    Min , Max      xx.x , xx.x  xx.x , xx.x  xx.x , xx.x  xx.x , xx.x  xx.x , xx.x  xx.x , xx.x  
                      
BMI (kg/m^2)    n  xx             xx             xx                xx   xx          xx                  
                        Mean ± SD  xx.x ± x.xx  xx.x ± x.xx  xx.x ± x.xx  xx.x ± x.xx  xx.x ± x.xx   xx.x ± x.xx  
                        Median         xx.x    xx.x   xx.x  xx.x   xx.x   xx.x 
    Min , Max      xx.x , xx.x  xx.x , xx.x  xx.x , xx.x  xx.x , xx.x  xx.x , xx.x  xx.x , xx.x  
 
___________________________________________________________________________________________________________ ______________________  
N: Number of subjects randomized in the specified treatment group  
n: Number of subjects                      
SD: Standard Devi ation 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 25 of 100 Table 14.1. 3 Summary of Demographics ( Double -blind Segment ) (continued)  
 
_______________________________________________ ___________________________________________________________________________________________  
 
                                                    Treatment Group   
        _________________________________________________________________ ________  
        
               EGT0001442       EGT0001442  EGT0001442  EGT0001442  
       Placebo  5 mg             10 mg          20 mg  50 mg          Overall           
Parameter         Statistic  (N=xx)        (N=xx)          (N=xx)          (N=xx)     (N=xx)         (N=xx)                                
___________________________________________________________________________________________________________________________ ______________  
 
Race      [n (%)]                          
   American Indian / Alaska Native   xx(xx.x%)      xx(xx.x%)        xx(xx.x%)     xx(xx.x%)  xx(xx.x%)     xx(xx.x%)                                             
   Asian      xx(xx.x%)      xx(xx.x%)        xx(xx.x%)     xx(xx.x%)  xx(xx.x%)      xx(xx.x%)                                          
 Black / African American    xx(xx.x%)      xx(xx.x%)        xx(xx.x%)     xx(xx.x%)  xx(xx.x%)     xx(xx.x%)                                           
 Native Haw aiian / Other Pacific Islander  xx(xx.x%)      xx(xx.x%)        xx(xx.x%)     xx(xx.x%)  xx(xx.x%)      xx(xx.x%)                                          
  White      xx(xx.x%)      xx(xx.x%)        xx(xx.x%)     xx(xx.x%)   xx(xx.x%)   xx(xx.x%)  
                                            
Gender     [n (%)]                          
   Male      xx(xx.x%)       xx(xx.x%)        xx(xx.x%)     xx(xx.x%)  xx(xx.x%)    xx(xx.x%)                                              
   Female      xx(xx.x%)      xx(xx.x%)        xx(xx.x%)     xx(xx.x%)   xx(xx.x%)   xx(xx.x%)  
 
Ethnicity      [n (%)]                          
   Hispanic or Latino                           xx(xx.x%)      xx(xx.x%)        xx(xx.x%)     xx(xx.x%)   xx(xx.x%)    xx(xx.x%)                                               
   Not Hispanic or Lat ino                       xx(xx.x%)      xx(xx.x%)        xx(xx.x%)     xx(xx.x%)  xx(xx.x%)    xx(xx.x%)                                            
                                            
___________________________________________________________________________________________________________ ________________ ______________  
N: Number of subjects randomized in the specified treatment group  
n: Number of subjects                      
%: Percentage based on N  
 
(Source: path \program name  Date /time of run: ddmmmyyyy:hh:mm)                                                                 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 26 of 100 Table 14.1. 4 Summary of Demographics (Dose Escalation Segment)  
     
 
______________________________________________________________________________________________________________________ __________  
                                     
                  Treatment Group   
              _________________________________________ _______________________    
       
             EGT0001442     EGT0001442    EGT0001442  EGT0001442  
            5 mg           10 mg         20 mg           50 mg          Overall 
Parameter        Statistic       (N=xx)      (N=xx)        (N=xx)   (N=xx)         (N=xx)                
____________________________________________________________________________________________________________ ____________________  
 
Age (years)    n                   xx             xx             xx             xx           xx                  
                        Mean ± SD           xx ± x.x  xx ± x.x   xx ± x.x   xx ± x.x   xx ± x.x  
                            Median              xx             xx             xx             xx           xx 
                           Min , Max           xx , xx  xx , xx  xx , xx  xx , xx  xx , xx 
                                                                                                                                                  
Height (cm)                 n                   xx             xx             xx             xx            xx                 
                        Mean ± SD           xx.x ± x.xx  xx.x ± x.xx   xx.x ± x.xx  xx.x ± x.xx   xx.x ± x.xx  
                            Median              xx.x   xx.x   xx.x   xx.x   xx.x 
                           Min , Max           xx.x , xx.x  xx.x , xx.x   xx.x , xx.x  xx.x , xx.x    xx.x , xx.x                                 
                                                                                                                                                  
Weight (kg)             n                   xx             xx             xx             xx            xx                 
                        Mean ± SD           xx.x ± x.xx  xx.x ± x.xx   xx.x ± x.xx  xx.x ± x.xx   xx.x ± x.xx  
                            Median              xx.x   xx.x   xx.x   xx.x   xx.x 
                           Min , Max           xx.x , x x.x xx.x , xx.x   xx.x , xx.x  xx.x , xx.x    xx.x , xx.x                
                      
BMI (kg/m^2)     n                   xx             xx             xx             xx             xx               
                        Mean ± SD           xx.x ± x.xx  xx.x ± x.xx   xx.x ± x.xx  xx.x ± x.xx   xx.x ± x.xx  
                            Median              xx.x   xx.x   xx.x   xx.x   xx.x 
                           Min , Max           xx.x , xx.x  xx.x , xx.x   xx.x , xx.x  xx.x , xx.x     xx.x , xx.x               
_____________________________________________________________________________________________________________________ _____________  
N: Number of subjects enrolled in the specified dose group  
n: Number of subjects                      
SD: Stand ard Deviation  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 27 of 100 Table 14.1. 4 Summary of Demographics (Dose Escalation Segment) (continued)  
 
_____________________________________________________________________________________________________________________________ _____________  
 
                                                    Treatment Group    
           ___________________________________ __________________ _______________     
               EGT0001442      EGT0001442   EGT0001442  EGT0001442  
              5 mg            10 mg              20 mg          50 mg          Overall 
Parameter        Statistic          (N=xx)        (N=xx)  (N=xx)        (N=xx)         (N=xx)               
____________________________________________________________________________________________________________ _____________________________  
 
Race        [n (%)]                          
   American Indian / Alaska  Native   xx(xx.x%)      xx(xx.x%)  xx(xx.x%)   xx(xx.x%)    xx(xx.x%)                                              
   Asian       xx(xx.x%)  xx(xx.x%)         xx(xx.x%)     xx(xx.x%)     xx(xx.x%)                                           
 Black / African American     xx(xx.x%)      xx(xx.x%)         xx(xx.x%)     xx(xx.x%)    xx(xx.x%)                                            
 Native Hawaiian / Other Pacific Islander   xx(xx.x%)      xx(xx.x%)         xx(xx.x%)     xx(xx.x%)    xx(xx.x%)                                            
  White       xx(xx.x%)      xx(xx.x%)         xx(xx.x%)     xx(xx.x%)   xx(xx.x%)  
                                            
Gender            [n (%)]                          
   Male       xx(xx.x%)      xx(xx.x%)         xx(xx.x%)     xx(xx.x%)   xx(xx.x%)                                               
   Female       xx(xx.x%)      xx(xx.x%)         xx(xx.x%)     xx(xx.x%)   xx(xx.x%)  
 
Ethnicity             [n (%)]                          
   Hispanic or Latino                                 xx(xx.x%)      xx(xx.x%)         xx(xx.x%)     xx(xx.x%)   xx(xx.x%)                                               
   Not Hispanic or Latino                             xx(xx.x%)      xx(xx.x%)         xx(xx.x%)     xx(xx.x%)   xx(xx.x%)                                             
                                            
____________________________________________________________________________________________________________________ ____________________  
N: Number of subjects randomized in the specified treatment group  
n: Number of subjects                      
%: Percentage based on N  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 28 of 100 Table 14.2.1 Primary Efficacy Analysis: Descriptive Summary of  Fasting Plasma Glucose  from Baseline  to End of Treatment  
Double -blind Segment  
Intent -to-Treat Analysis Set  
 
_____________________________________________________________________________________________________________________________ _________ ____ 
 
                                                     Treatment Group   
       _____________________________________________________________________________________  
 
          EGT0001442       EGT0001442        EGT0001442        EGT0001442                    
                                                 Placebo         5 mg            10 mg             20 mg       50 mg                   
                          Statistic      (N=xx)          (N=xx)           (N=xx)             (N=xx)           (N=xx) 
_____________________________________________________________________________________________________________________________ _________ ____ 
 
Baseline *           n               xx               xx               xx      xx                xx       
                   Mean ± SD       xx.x ± x.xx      xx.x  ± x.xx      xx.x ± x.xx  xx.x ± x.xx       xx.x ± x.xx       
                             Median          xx.x             xx.x             xx.x      xx.x              xx.x              
                            Min, Max        xx , xx          xx , x x          xx , xx   xx , xx           xx , xx  
 
End of Treatment #                n               xx               xx               xx      xx                xx                                                          
     Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx  xx.x ± x.xx       xx.x ± x.xx       
                             Median          xx.x             xx.x             xx.x      xx.x              xx.x              
                             Min, Max        xx , xx          xx , xx          xx , xx   xx , xx           xx , xx           
 
Change from Baseline to          n               xx               xx               xx      xx                xx                                                          
End of Treatment    Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx  xx.x ± x.xx       xx.x ± x.xx       
                             Median          xx.x             xx.x             xx.x      xx.x              xx.x              
                             Min, Max        xx , xx          xx , xx          xx , xx   xx , xx           xx , xx  
  
_____________________________________________________________________________________________________________________________ _________ ____ 
Note: * Baseline is defined as the mean of FPG values on day -2 and day 1. 
      # End of Treatment is  defined as the mean of FPG values on day 27 and d ay 29. 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 29 of 100 Table 14.2.2 Primary Efficacy Analysis: ANCOVA Results on Mean Change in FPG from Baseline  to End of Treatment  
Double -blind Segment  
Intent -to-Treat  Analysis Set  
 
_____________________________________________________________________________________________________________________________ _____________  
                                                           
                          Difference between Treatment s  
                    ________________________________________________                                       
             
Treatment                  n    LSMeans  Std Err      LSMeans   Std Err    95%-confidence  P -value      P-value   P-value 
                                                    LSMeans                 LSMeans    Interval        Treatment    Baseline  Center 
____________ _____________________________________________________________________________________________________________________________ _ 
                                                                                                
Overall     xxx          x.xxxx   x.xxxx   x.xxxx 
 
Placebo      xxx    x.xxx   x.xxx  
 
5 mg EGT0001442  vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
10 mg EGT0001442  vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
20 mg EGT0001442  vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
50 mg EGT0001442  vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
_____________________________________________________________________________________________________________________________ ____________                 
n:               Number of subjects with data available in the specific treatment group                                         
LSMeans:         Least square means  
Std Err LSMeans: Standard error of the LSMeans   
Note:            LSMeans, Std Err of LSMeans, 95% confidence intervals and p -values are based on an ANCOVA with change from baseline as  
                 dependent variable and treatment as fixed effect and base line and center  as covariate s. P-values are from two -sided test  
                 at 5%-level. 
Note: Baseline is defined as the mean of FPG values on day -2 and day 1. 
      End of T reatment is  defined as the mean of FPG values on day 27 and d ay 29. 
 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)  
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 30 of 100 Similar tables:  
 
 
Table 14.2. 3 Descriptive Summary of Fasting Plasma Glucose from Baseline  to End of Treatment  
Double -blind Segment  
Per-Protocol Analysis Set  
 
Table 14.2. 4 ANCOVA Results on Mean Change in FPG from Baseline  to End of Treatment   
Double -blind Segment  
Per-Protocol Analysis Set  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 31 of 100   
 
Table 14.2. 5 Descriptive Summary of F asting Plasma Glucose  from End of T reatment to Post Treatment  
Double -blind Segment  
Intent -to-Treat Analysis Set  
 
_____________________________________________________________________________________________________________________________ _____________  
 
                                                     Treatment Group   
       _____________________________________________________________________________________  
 
          EGT0001442       EGT0001442        EGT0001442        EGT0001442                    
                                                 Placebo         5 mg             10 mg             20 mg       50 mg                   
                          Statistic      (N=xx)          (N=xx)           (N=xx)             (N=xx)           (N=xx)  
______________________________ ____________________________________________________________________________________________________________  
 
End of Treatment#                n               xx               xx               xx      xx                xx                                                          
     Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx  xx.x ± x.xx       xx.x ± x.xx       
                             Median          xx.x             xx.x             xx.x      xx.x              xx.x              
                             Min, Max        xx , xx          xx , xx          xx , xx   xx , xx           xx , xx           
 
Post Treatment+    n               xx               xx               xx      xx                xx                                                          
     Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx  xx.x ± x.xx       xx.x ± x.xx       
                             Median          xx.x             xx.x             xx.x      xx.x              xx.x              
                             Min, Max        xx , xx          xx , xx          xx , xx   xx , xx           xx , xx                                      
 
Change from End of Treatment to  n               xx               xx               xx      xx                xx                                                          
Post Treatment    Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx  xx.x ± x.xx       xx.x ± x.xx       
                             Median          xx.x             xx.x             xx.x      xx.x              xx.x              
                             Min, Max        xx , xx          xx , xx          xx , xx   xx , xx           xx , xx                    
____________________________________________________________________________ ______________________________________________________________  
Note: # End of Treatment is  defined as the mean of FPG values on day 27 and d ay 29. 
      + Post T reatment is determined from the blood samples drawn at week 4 of treatment, defined as the mean  of FPG values on day 27 and  
        day 29 to week 6, defined as the mean of FPG values on day 41 and day 43.  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
 
                                                               
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 32 of 100 Table 14.2. 6 ANCOVA Results on Mean Change in FPG from End of Treatment to Post Treatment  
Double -blind Segment  
Intent -to-Treat Analysis Set  
 
_____________________________________________________________________________________________________________________________ _____________  
                                                           
                          Difference between Treatments  
                    ________________________________________________                                      
             
Treatment                  n    LSMeans  Std Err      LSMeans   Std Err    95%-confidence  P -value      P-value   P-value 
                                                    LSMeans                 LSMeans    Interval        Treatment    Baseline  Center 
_____________________________________________________________________________________________________________________________ _____________  
                                                                                                
Overall     xxx          x.xxxx   x.xxxx   x.xxxx 
 
Placebo      xxx    x.xxx   x.xxx  
 
5 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
10 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
20 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
50 mg EGT0001442 vs . Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
__________________________________________________________________________________________________________________________ _______________                 
n:               Number of subjects with data available in the specific treatment group                                         
LSMeans:         Least square means  
Std Err LSMeans: Standard error of the LSMeans   
Note:            LSMeans, Std Err of LSMeans , 95% confidence intervals and p -values are based on an ANCOVA with change from baseline as  
                 dependent variable and treatment as fixed effect and baseline and center as covariates. P -values are from two -sided test  
                 at 5%-level. 
Note: End of Treatment is  defined as the mean of FPG values on day 27 and d ay 29. 
      Post Treatment is determined from the blood samples drawn at week 4 of treatment, defined as the mean of FPG values on day 27 and  
      day 29 to week 6, defined  as the mean of FPG values on day 41 and day 43.  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 33 of 100 Table 14.2. 7 Descriptive Summary of Change in Body Weight  from Baseline to Day 29  
Double -blind Segment  
 Intent -to-Treat Analysis Set  
 
_____________________________________________________________________________________________________________________________ _____________  
 
                                                    Treatment Group   
           _____________________________________________________________________________________  
 
           EGT0001442       EGT0001442        EGT0001442        EGT0001442                    
                                                   Placebo         5 mg  10 mg     20 mg       50 mg                   
                          Statistic             (N=xx)          (N=xx)           (N=xx)             (N=xx)           (N=xx)  
_________________________________________________________________ _________________________________________________________________________  
 
Baseline            n                xx               xx               xx     xx                xx      
                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx           
  
Day 29                     n                xx               xx               xx     xx                xx                                                          
     Mean ± SD        xx.x ± x.xx      xx .x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx           
                                      
Change from baseline            n                xx               xx               xx     xx                xx                                                          
     Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx           
_____________________________________________________________________________________________________________________________ _____________  
Note: Baseline is defined as the pre -dose body weight  value on Day 1 . 
 
 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 34 of 100 Table 14.2. 8 ANCOVA Results on Mean Change in Body Weight  from Baseline  to Day 29   
Double -blind Segment  
Intent -to-Treat Analysis Set  
 
_____________________________________________________________________________________________________________________________ _____________  
                                                           
                          Difference between Treatments  
                    ________________________________________________                                      
             
Treatment                  n    LSMeans  Std Err      LSMeans   Std Err    95%-confidence  P -value      P-value   P-value 
                                                    LSMeans                 LSMeans    Interval        Treatment    Baseline  Center 
_________________________________________________________ _________________________________________________________________________________  
                                                                                                
Overall     xxx          x.xxxx   x.xxxx   x.xxxx 
 
Placebo      xxx    x.xxx   x.xxx  
 
5 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
10 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
20 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
50 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
_____________________________________________________________________________________________________________________________ ____________                 
n:               Number of subjects with data available in the specific treatment group                                         
LSMeans:         Least square means  
Std Err LSMeans: Standard error of the LSMeans   
Note:            LSMeans, Std Err of LSMeans, 95% confidence intervals and p -values are based on an ANCOVA with change from baseline as  
                 dependent variable and treatment as fixed effect and baseline and center as covariates. P -values are from two -sided test  
                 at 5%-level. 
Note: Baseline is defined as the pre -dose body weight  value on Day 1 . 
 
 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 35 of 100 Table 14.2. 9 Descriptive Summary of Change in HbA1c  from Baseline  to Day 29   
Double -blind Segment  
 Intent -to-Treat Analysis Set  
 
_____________________________________________________________________________________________________________________________ _____________  
 
                                                    Treatment Group   
           _____________________________________________________________________________________  
 
           EGT0001442       EGT0001442        EGT0001442        EGT0001442                    
                                                   Placebo         5 mg  10 mg     20 mg       50 mg                   
                          Statistic             (N=xx)          (N=xx)           (N=xx)             (N=xx)           (N=xx)  
_____________________________________________________________________________________ _____________________________________________________  
 
Baseline            n                xx               xx               xx     xx                xx      
                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx           
  
Day 29                     n                xx               xx               xx     xx                xx                                                          
     Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx   xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , x x     xx , xx           xx , xx           
                                      
Change from baseline            n                xx               xx               xx     xx                xx                                                          
     Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx           
_____________________________________________________________________________________________________________________________ _____________  
Note: Baseline is defi ned as the pre -dose HbA1c value on Day 1 . 
 
 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 36 of 100 Table 14.2. 10 ANCOVA Results on Mean Change in HbA1c  from Baseline  to Day 29  
Double -blind Segment  
Intent -to-Treat Analysis Set  
 
_____________________________________________________________________________________________________________________________ _____________  
                                                           
                          Difference between Treatments  
                    ________________________________________________                                      
             
Treatment                  n    LSMeans  Std Err      LSMeans   Std Err    95%-confidenc e  P-value      P-value   P-value 
                                                    LSMeans                 LSMeans    Interval        Treatment    Baseline  Center 
_________________________________________________________________________________________ _________________________________________________  
                                                                                                
Overall     xxx          x.xxxx   x.xxxx   x.xxxx 
 
Placebo      xxx    x.xxx   x.xxx  
 
5 mg EGT0001442 vs. Pla cebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
10 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
20 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
50 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
________________________________________________________________________________________________________________ _________________________                 
n:               Number of subjects with data available in the specific treatment group                                         
LSMeans:         Least square means  
Std Err LSMeans: Standard error of the LSMeans   
Note:            LSMeans, Std Err of LSMeans, 95% confidence intervals and p -values are based on an ANCOVA with change from baseline as  
                 dependent variable and treatment as fixed effect and baseline and center as covariates. P -values are fr om two-sided test  
                 at 5%-level. 
Note: Baseline is defined as the pre -dose HbA1c value on Day 1 . 
 
 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 37 of 100 Table 14.2. 11 Descriptive Summary of Change in 24 h UGE  from Baseline to Day 28  
Double -blind Segment  
 Intent -to-Treat Analysis Set  
 
_____________________________________________________________________________________________________________________________ _____________  
 
                                                    Treatment Group   
           ____________________________________ _________________________________________________  
 
           EGT0001442       EGT0001442        EGT0001442        EGT0001442                    
                                                   Placebo         5 mg  10 mg     20 mg       50 mg                   
                          Statistic             (N=xx)          (N=xx)           (N=xx)             (N=xx)           (N=xx)  
_____________________________________________________________________________________________________________________________ _____________  
 
Baseline            n                xx               xx               xx     xx                xx      
                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx           
  
Day 1                     n                xx               xx               xx     xx                xx                                                          
     Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
 
Day 28                     n                xx               xx               xx     xx                xx                                                          
     Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx                    
                                      
Change from baseline            n                xx               xx               xx     xx                xx                                                          
to Day 1     Mean ± SD        xx.x ± x. xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx   
 
Change from baseline            n                xx               xx               xx     xx                xx                                                          
to Day 28     Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx                   
_____________________________________________________________________________________________________________________________ _____________  
Note: Baseline is defined as the 24h UGE on Day 0. 
 
 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 38 of 100 Table 14.2. 12 ANCOVA Results on Mean Change in 24 h UGE  from Baseline  to Day 28   
Double -blind Segment  
Intent -to-Treat Analysis Set  
 
_____________________________________________________________________________________________________________________________ _____________  
                                                           
                          Difference between Treatments  
                    ________________________________________________                                      
             
Treatment                  n    LSMeans  Std Err      LSMeans   Std Err    95%-confidence  P -value      P-value   P-value 
                                                    LSMeans                 LSMeans    Interval        Treatment    Baseline  Center 
____________________________________________________________________________ ______________________________________________________________  
                                                                                                
Overall     xxx          x.xxxx   x.xxxx   x.xxxx 
 
Placebo      xxx    x.xxx   x.xxx  
 
5 mg EGT00 01442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
10 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
20 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
 
50 mg EGT0001442 vs. Placebo     xxx    x.xxx   x.xxx     x.xxx     x.xxx     x.xxx, x.xxx    x.xxxx   
____________________________________________________________________________________________________________ _____________________________                 
n:               Number of subjects with data available in the specific treatment group                                         
LSMeans:         Least square means  
Std Err LSMeans: Standard error of the LSMeans    
Note:            LSMeans, Std Err of LSMeans, 95% confidence intervals and p -values are based on an ANCOVA with change from baseline as  
                 dependent  variable and treatment as fixed effect and baseline and center as covariates. P -values are from two -sided test  
                 at 5%-level. 
Note: Baseline is defined as the 24h UGE on Day 0. 
 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:m m)                                    
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 39 of 100 Table 14.2.1 3 Summary of Plasma  Concentrations of EGT0001442  (ng/mL )  
 Dose Escalation Seg ment  
 
________________________________________________________________________________________________________________ _______________  
   
Dose        Subject  0 0.5 1 2 3  4 6 8 10 12 24  48  
Group    Center    Number  hr hr hr hr hr hr hr hr hr  hr hr hr  
________________________________________________________________________________________________________________ _______________  
5 mg EGT0001442    01     01  xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx 
       02  xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx  
       03  xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx xxxx  
 
     ... 
 
 
   
 
       N          xx xx xx xx xx xx xx xx xx xx xx xx 
       MEAN       xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx 
       SD         xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx  
       CV%        xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx  
       MEDIAN     xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx  
       MIN        xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx  
       MAX        xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx xx.xx 
_________________________________________________________________________________________________________________ ______________  
 
Note: table will continue for 10mg, 20mg and 50mg dose groups.  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)            
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 40 of 100 Table 14.2. 14 Summary of Pharmacokinetic Parameters of EGT0001442  
 Dose Escalation Segment  
 
________________________________________________________________________________________________________________ _______________  
              
             _________Ln -Transformed______ _____                     
Dose    Subject AUC0-t    AUC0-24  AUC0-inf  Cmax   Tmax  Thalf Kel  Vz/F  CL/F  AUC0-t   AUC0-24  AUC0-inf  Cmax    
Group           Number (ng.h/mL)  (ng.h/mL)  (ng.h/mL) (ng/mL) (h)   (h)   (1/h)  (L)  (L/h) (ng.h/mL)(ng.h/mL) (ng.h/mL)  (ng/mL)      
________________________________________________________________________________________________________________ _______________  
5 mg EGT0001442   01    xxxx.x    xxxx.x   xxxx.x    xxx.x   xx.x   xx.x x.xxxx   xxx.x   xxx.x   xxx.x     xxx.x     xxx.x       
    02  xxxx.x    xxxx.x   xxxx.x    xxx.x   xx.x   xx.x x.xxxx   xxx.x   xxx.x   xxx.x     xxx.x     xxx.x      
   
      ... 
 
 
   
 
    N        xxxx.x    xxxx.x   xxxx.x    xxx.x   xx.x   xx.x x.xxxx   xxx.x   xxx.x   xxx.x     xxx.x     xxx.x       
    MEAN     xxxx.x    xxxx.x   xxxx.x    xxx.x   xx.x   xx.x x.xxxx   xxx.x   xxx.x   xxx.x     xxx.x     xxx.x       
    SD       xxxx.x    xxxx.x   xxxx.x    xxx.x   xx.x   xx.x x.xxxx   xxx.x   xxx.x   xxx.x     xxx.x     xxx.x       
    CV%      xxxx.x    xxxx.x   xxxx.x    xxx.x   xx.x   xx.x x.xxxx   xxx.x   xxx.x   xxx.x     xxx.x     xxx.x       
    MEDIAN   xxxx.x    xxxx.x   xxxx.x    xxx.x   xx.x   xx.x x.xxxx   xxx.x   xxx.x   xxx.x     xxx.x     xxx.x       
    MIN      xxxx.x    xxxx.x   xxxx.x    xxx.x   xx.x   xx.x x.xxxx   xxx.x   xxx.x   xxx.x     xxx.x     xxx.x       
    MAX      xxxx.x    xxxx.x   xxxx.x    xxx.x   xx.x   xx.x x.xxxx   xxx.x   xxx.x   xxx.x     xxx.x     xxx.x       
    GM*  xxxx.x    xxxx.x    xxxx.x    xxx.x    
________________________________________________________________________________________________________________ _______________  
Note: *GM = Geometric Mean  
 
Note: table will continue for 10mg, 20mg and 50mg dose groups.  
 
 
(Source: path \program name  Date /time of run: ddmmmyyyy:hh:mm)            
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 41 of 100 Table 14.2. 15 Summary of Post Prandial Blood Glucose (mg/dL)  in Change from Day 0 to Day 2   
Dose Escalation Segment                          
_______________________________________________________________________ _____________________________________ _____________________  
                 Dose Group  
                         ________________________________________________ _________________________              
         EGT0001442       EGT0001442       EGT0001442       EGT0001442                    
          5 mg           10 mg          20 mg          50 mg                  
Day   Meal  Statistic          (N=xx)           (N=xx)           (N=xx)           (N=xx)          
____________________________________________________________________________________________________________ _____________________  
Day 0          Breakfast  n                xx               xx               xx     xx                   
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
    Lunch    n                xx               xx               xx     xx                     
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
    Dinner  n                xx               xx               xx     xx                     
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
Day 2          Breakfast  n                xx               xx               xx     xx                    
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
    Lunch    n                xx               xx               xx     xx                
                                       Mean ± SD        xx.x ± x.xx      xx.x ± x .xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
    Dinner  n                xx               xx               xx     xx                   
                                       Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
Change from Day 0       Breakfast  n                xx               xx               xx     xx                  
to Day     Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
    Lunch    n                xx               xx               xx     xx                
                                       Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
    Dinner  n                xx               xx               xx     xx                   
                                       Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
_______________________________________________ _____________________________________________________________________________ _____ 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 42 of 100 Table 14.2. 16 Summary of Post Prandial Blood Glucose in AUC (mg.h/dL ) 
Dose Escalation Segment        
                    
____________________________________________________________________________________________________________ __________________________  
                  
           Dose Group  
                         __________________________________________________ ___________________________             
         EGT0001442       EGT0001442       EGT0001442       EGT0001442                    
          5 mg           10 mg          20 mg          50 mg                  
Day     Statistic          (N=xx)           (N=xx)           (N=xx)           (N=xx)          
____________________________________________________________________________________________________________ __________ ________________  
 
Day 0            n                xx               xx               xx     xx                   
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
 
Day 2            n                xx               xx               xx     xx                     
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
       
Change from Day 0 to Day 2        n                xx               xx               xx     xx                
                                       Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
  
     
___________________________________________________________________________________________________________ ___________________________  
(Source: path \program na me  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
      
      
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 43 of 100 Table 14.3.1 .1 Summary of T EAEs  
Double -blind Segment  
 Double -blind Safety Analysis Set  
             
_______________________________________________________________________________________________________ ________________________  
  
                                                   Treatment Group   
         _________________________________________________ _________________________ _________________  
 
          EGT0001442         EGT0001442           EGT0001442         EGT0001442                    
                                      Placebo             5 mg               10 mg           20 mg              50 mg                   
                               (N=xx)             (N=xx)             (N=xx)               (N=xx)              (N=xx) 
________________________________________________________________________________________________________ ___________ ____________                     
All TEAEs       xx ( xx.x%) E       xx ( xx.x%) E       xx ( xx.x%) E  xx ( xx.x%) E    xx ( xx.x%) E                           
Deaths       xx ( xx.x%) E       xx ( xx.x%) E       xx ( xx.x%) E  xx ( xx.x%) E    xx ( xx.x%) E                          
Serious TEAEs       xx ( xx.x%) E       xx ( xx.x%) E       xx ( xx.x%) E  xx ( xx.x%) E    xx ( xx.x%) E                           
TEAEs leading to withdrawal     xx ( xx.x%) E       xx ( xx.x%) E       xx ( xx.x%) E  xx ( xx.x%) E    xx ( xx.x%) E                         
TEAEs related to study drug     xx ( xx.x%) E       xx ( xx.x%) E       xx ( xx.x%) E  xx ( xx.x%) E    xx ( xx.x%) E                            
   
______________________________________________________________________________________________________ _________________________  
N:  Number of subjects exposed in specified group                      
%:  Percentage based on N  
E:  Number of TEAEs  
 
 
 (Source: path\program name  Date/time of run: ddmmmyyyy:hh:mm)                                                            
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 44 of 100 Table 14.3.1.2 Summary of T EAEs   
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
             
_______________________________________________________________________________________________________ ________________________  
  
                                                   Dose Group  
         ______________________________________________________ _____________________________________  
 
           EGT0001442         EGT00014 42           EGT0001442        EGT0001442                    
                                       5 mg           10 mg           20 mg           50 mg                  
                                (N=xx)             (N=xx)               (N=xx)            (N=xx)               
_______________________________________________________________________________________________________ ________________________                      
All TEAEs        xx ( xx.x%) E      xx ( xx.x%) E      xx ( xx.x%) E  xx ( xx.x%) E                               
Deaths         xx ( xx.x%) E      xx ( xx.x%) E      xx ( xx.x%) E  xx ( xx.x%) E                            
Serious TEAEs         xx ( xx.x%) E      xx ( xx.x%) E      xx ( xx.x%) E  xx ( xx.x%) E      
TEAEs leading to study disc ontinuation xx ( xx.x%) E      xx ( xx.x%) E      xx ( xx.x%) E  xx ( xx.x%) E                                                       
TEAEs related to study drug       xx ( xx.x%) E      xx ( xx.x%) E      xx ( xx.x%) E  xx ( xx.x%) E                               
   
______________________________________________________________________________________________________ _________________________  
N:  Number of subjects exposed in s pecified group                     
%:  Percentage based on N  
E:  Number of TEAEs  
 
 
Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                            
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 45 of 100 Table 14.3. 1.3 Summary of TEAEs  by System Organ Class, Preferred Term and Treatment Group  
Double -blind Segment   
 Double -blind Safety Analysis Set  
    
___________________________________________________________________________________________________________________ ___________________  
 
                                                   Treatment Group   
               ___________________________________________________________ __________________________  
             
              EGT0001442         EGT0001442        EGT0001442         EGT0001442                    
System Organ Class                         Placebo             5 mg           10 mg            20 mg        50 mg                   
   Preferred Term                        (N=xx)              (N=xx)             (N=xx)             (N=xx)             (N=xx)                                         
____________________________________________________________________________________________________________________ ____________ ______                     
 
Subject with at least one AE    xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
 
SOC 1     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)   
   PT1     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
 PT2     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
   PTxx      xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
 
SOC 2     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)   
   PT1     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
 PT2     xx ( xx.x%)         xx ( xx.x%)        xx ( x x.x%)        xx ( xx.x%)        xx ( xx.x%)  
   PTxx      xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
 
        xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)   
SOC 3       
 
____________________________________________________________________________________________________________________ __________________  
Note: Counts reflect numbers of subjects reporting one or more adverse events that map to the MedDRA system organ clas s/preferred  
      term.  At each level of summarization (system organ class or preferred term), subjects reporting more than one adverse event are  
      counted only once (under the greatest reported severity).  
Note: N: Number of subjects in the specifi ed group  
      %: Percentage based on N  
 
Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                            
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 46 of 100  
Similar tables:  
 
Table 14.3. 1.4 Summary of Drug -related TEAEs  by System Organ Class, Preferred Term and Treatment Group  
Double -blind Segment   
 Double -blind Safety Analysis Set  
 
Table 14.3. 1.5 Summary of TEAEs Leading to Study Discontinuation  by System Organ Class, Preferred Term and Treatment 
Group  
Double -blind Segment   
 Double -blind Safet y Analysis Set  
 
Table 14.3. 1.6 Summary of Serious TEAEs  by System Organ Class, Preferred Term and Treatment Group  
Double -blind Segment   
 Double -blind Safety Analysis Set  
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 47 of 100 Table 14.3. 1.7 Summary of T EAEs  by System Organ Class, Preferred Term and Dose  Group  
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
    
___________________________________________________________________________________________________________________ ________________________  
                                                     
                  Dose Group  
                  ___________________________________________________________ ___________________  
              
       EGT0001442           EGT0001442         EGT0001442         EGT0001442                    
System Organ Class                               5 mg        10 mg  20 mg            50 mg                  
   Preferred Term                               (N=xx)               (N=xx)             (N=xx)             (N=xx)              
___________________________________________________________________________________________________________________ ________________________                        
 
Subject with at least one AE      xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx  ( xx.x%)         
 
SOC 1       xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
   PT1       xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
 PT2       xx ( xx.x%)         xx ( xx.x%)        xx ( x x.x%)        xx ( xx.x%)         
   PTxx        xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
 
SOC 2       xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
   PT1       xx ( xx.x%)         xx ( x x.x%)        xx ( xx.x%)        xx ( xx.x%)         
 PT2       xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
   PTxx        xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
 
            xx ( xx.x %)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
SOC 3       
 
_________________________________________________________________________________________________________________ __________________________  
Note: Counts reflect numbers of subjects reporting one or more adverse events that map to the MedDRA system organ class/preferred  
      term.  At each level of summarization (system organ class or preferred term), subjects reporting more than one adverse event are  
      counted only once  (under the greatest reported severity).  
Note: N: Number of subjects in the specified group  
      %: Percentage based on N  
 
Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                            
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 48 of 100 Similar  tables:  
 
Table 14.3. 1.8 Summary of Drug -related TEAEs by System Organ Class, Preferred Term and Dose  Group  
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
 
Table 14.3. 1.9 Summary of TEAEs Leading to Study Discontinuation by System Organ Class, Preferred Term and Dose  Group  
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
 
Table 14.3. 1.10 Summary of Serious TEAEs by System Organ Class, Preferred Term and Dose  Group 
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 49 of 100 Table 14.3. 1.11 Summary of TEAEs  by Maximum Severity  
Double -blind Segment   
 Double -blind Safety Analysis Set  
 
___________________________________________________________________________________________________________________ ________________________  
 
                                                    Treatment Group   
                       _______________________ ____________________________________________________________________  
             
               EGT0001442         EGT0001442         EGT0001442         EGT0001442                    
System Organ Class                                Placebo             5 mg  10 mg     20 mg        50 mg                   
   Preferred Term          Severity         (N=xx)              (N=xx)             (N=xx)             (N=xx)             (N=xx)                                             
____________________________________________________________________________________________________________________ _______________________                       
Subject with at least one AE  Mild    xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)   
     Moderate   xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
     Severe     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x %) 
 
SOC 1    Mild     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)   
     Moderate   xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
     Severe     xx ( xx.x%)         xx  ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
  
  PT1    Mild     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)   
     Moderate   xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
     Severe     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
 
  PTxx    Mild     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)   
     Moderate   xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
     Severe     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
 
SOC 2    Mild     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
     Moderate   xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
     Severe     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)   
____________________________________________________________________________________________________________________ _______________________  
Note: Counts reflect num bers of subjects reporting one or more adverse events that map to the MedDRA system organ class/preferred  
      term.  At each level of summarization (system organ class or preferred term), subjects reporting more than one adverse event are  
      counted only once (under the greatest reported severity).  
Note: N: Number of subjects in the specified group  
      %: Percentage based on N  
 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 50 of 100 Table 14.3. 1.12 Summary of T EAEs  by Maximum Severity  
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
 
___________________________________________________________________________________________________________________ ________________________  
 
                                                    Treatment Group                                           
                                            ___________________________________________________________________________________________  
             
         EGT0001442          EGT0001442         EGT0001442         EGT0001442                    
System Organ Class                                  5 mg               10 mg         20 mg            50 mg                  
   Preferred Term           Severity         (N=xx)              (N=xx)             (N=xx)             (N=xx)                                                         
__________________________________________________________________________________________________________________ _________________________                         
Subject with at least one AE   Mild    xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)           
      Moderate   xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)          
      Severe     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
 
SOC 1     Mild     xx ( xx.x%)         x x ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)          
      Moderate   xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
      Severe     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
         
  PT1     Mild     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
      Moderate   xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
      Severe     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)  
        
  PTxx     Mild     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
      Moderate   xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
      Severe     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)          
 
SOC 2     Mild     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)          
      Moderate   xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)         
      Severe     xx ( xx.x%)         xx ( xx.x%)        xx ( xx.x%)        xx ( xx.x%)           
____________________________________________________________________________________________________________________ _______________________  
Note: Counts reflect numbers of subjects reporting one or more adverse events that map to the MedDRA system organ class/preferred  
      term.  At each level of summarization (system organ class or preferred term), subjects reporting more than one adverse event are  
      counted only once (under the greatest reported severity).  
Note: N: Number of subjects in the specified group  
      %: Percentage based on N  
 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
 
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 51 of 100 Table 14.3. 1.13 Clinical Laboratory Evaluations in Biochemistry  (Observed Values)   
Double -blind Segment   
 Double -blind Safety Analysis Set  
                          
_____________________________________________________________________________________________________________________________ ______________  
                                          
           Treatment Group   
                    ___________________________________________________________________________________________  
             
            EGT0001442       EGT0001442       EGT0001442        EGT0001442                    
         Visit    Placebo    5 mg  10 mg     20 mg       50 mg                  
        Day Statistic          (N=xx)           (N=xx)           (N=xx)           (N=xx)            (N=xx)                                           
_____________________________________________________________________ _______________________________________ _______________________________  
 
Albumin (G/L)     Screening  n                xx               xx               xx     xx                xx       
(30 - 50)                  Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx   
       Day -2 n                xx               xx               xx     xx                xx      
                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
       Day 1 n                xx               xx               xx     xx                xx      
                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx           
                         ... 
         
  
ALT(SGPT)  (U/L)      Screening   n                xx               xx               xx     xx                xx                                                          
(8 – 54)    Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          x x , xx          xx , xx     xx , xx           xx , xx           
                                      
... 
_____________________________________________________________________________________________________________________________ ______________  
  
Note: Table will continue fo r other visit day s 2, 8, 15, 22, 29, 35 and 43  and will continue for other lab parameters.  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 52 of 100  
Table 14.3. 1.14 Clinical Laboratory Evaluations in Change from Baseline in Biochemistry  
Double -blind Segment   
 Double -blind Safety Analysis Set  
                          
__________________________________________________________________________________________________ __________ _______________________________  
                                          
           Treatment Group   
                    ___________________________________________________________________________________________  
             
            EGT0001442       EGT0001442       EGT0001442        EGT0001442                    
         Visit    Placebo    5 mg  10 mg     20 mg       50 mg                  
        Day Statistic          (N=xx)           (N=xx)           (N=xx)           (N=xx)            (N=xx)                                           
_____________________________________________________________________________________________________________________________ ______________  
 
Albumin (G/L)      Day 2 n                xx               xx               xx     xx                xx       
(30 - 50)                        Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
                                 P-value*              x.xxxx     x.xxxx   x.xxxx     x.xxxx       x.xxxx 
 
        Day 8 n                xx               xx               xx     xx                xx      
                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
     P-value*              x.xxxx     x.xxxx   x.xxxx     x.xxxx       x.xxxx 
      
                         ... 
         
  
ALT(SGPT)  (U/L)        Day 2     n                xx               xx               xx     xx                xx  
(8 – 54)                         Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
     P-value*              x.xxxx     x.xxxx   x.xxxx     x.xxxx       x.xxxx           
                                      
... 
______________________________________ _____________________________________________________________________ _______________________________  
Note: Baseline is defined as the last observed measurement prior to dosing  on Day 1 at Visit 5 . 
Note: *P -values are from paired t -test. 
Note: Table will co ntinue for other visit days 15, 22, 29, 35 and 43  and will continue for other lab parameters.  
 
 
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 53 of 100 Table 14.3. 1.15 Biochemistry Laboratory Shift Table  
Double -blind Segment   
 Double -blind Safety Analysis Set  
      
_______________________________________________________________________________________________________ ____________________________  
 
                                                                                  Day 1 / Baseline                 
                                                    ________________________________________________ ___________________________  
                                                                          
Lab                           Visit       Missing      Below LLNR    Normal      Above ULNR      Total      
Parameter        Treatment       Day       n (%)        n (%)         n (%)       n (%)           n (%)    
_______________________________________________________________________________________________ ____________________________________  
                                                                                        
Albumin ( G/L)    Placebo (N=xx) Day 2  Missing           xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)      xx ( xx.x)  
(30 - 50)                                 Below LLNR        xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)      xx ( xx.x)  
                             Normal            xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)      xx ( xx.x)  
                             Above ULNR        xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)      xx ( xx.x)  
                             Total             xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)      xx (100.0)  
                                                                                                      
                 Day 8  Missing           xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)      xx ( xx.x)  
                             Below LLNR        xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)      xx ( xx.x)  
                              Normal            xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)      xx ( xx.x)  
                             Above ULNR        xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)      xx ( xx.x)  
                             Total             xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)      xx (100.0)  
     ... 
 
       EGT0001442 5 mg (N=xx)    
 
... 
 
____________________________________________________ _____________________________________________________________________________ _ 
Note:  N: Number of subjects in the specified group  
     n: Number subjects with data available  
       %: Percentage based on N  
    LLNR: Lower Limit of Normal Range  
    ULNR: Upper Limit of Normal Range      
 
Table will continue for other visit days 15, 22, 29, 35 and 43  and for other treatment group and other lab parameters.  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 54 of 100  
Similar  tables:      
Table 14.3. 1.16 Clinical Laboratory Evaluations in Hematology  (Observed Values)   
Double -blind Segment   
 Double -blind Safety Analysis Set  
 
Table 14.3. 1.17 Clinical Laboratory Evaluations in Change from Baseline in Hematology  
Double -blind Segment   
 Double -blind Safety Analysis Set  
 
Table 14.3. 1.18 Hematology  Laboratory Shift Table  
Double -blind Segment   
 Double -blind Safety Analysis Set  
 
Table 14.3. 1.19 Clinical Laboratory Evaluations in Urinalysis (Observed Values)   
Double -blind Segment   
 Double -blind Safety Analysis Set  
 
Table 14.3. 1.20 Clinical Laboratory Evaluations in Change from Baseline in Urinalysis  
Double -blind Segment   
 Double -blind Safety Anal ysis Set  
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 55 of 100 Table 14.3. 1.21 Urinalysis Laboratory Shift Table  
Double -blind Segment   
 Double -blind Safety Analysis Set  
      
_______________________________________________________________________________________________________ __________________________  
 
                                                                             Day 1 / Baseline  
                                                    ________________________________ _______________________________   
                                                                          
Lab                           Visit       Missing      Normal       Abnormal     Total      
Parameter        Treatment       Day       n (%)        n (%)        n (%)        n (%)              
___________________________________________________________________________________________________ ______________________________  
                                                                                        
Albumin ( G/L)    Placebo (N=xx)   Day 2   Missing          xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)       
(30 - 50)                                 Normal           xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)       
                              Abnormal         xx ( xx.x )   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)       
                              Total            xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx (100.0)  
                                                                                                     
     Day 8   Missing          xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)       
                               Normal           xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)       
                              Abnormal         xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx ( xx.x)       
                              Total            xx ( xx.x)   xx ( xx.x)   xx ( xx.x)   xx (100.0)  
     ... 
 
       EGT0001442 5 mg (N=xx)    
 
... 
 
_____________________________________________________________________________________________________ ____________________________  
Note:  N: Number of subjects in the specified group  
     n: Number subjects with data available  
       %: Percentage based on N 
    
 
Table will continue for other visit days 15, 22, 29, 35 and 43  and for other treatment group and other lab parameters.  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 56 of 100 Table 14.3. 1.22 Clinical Laboratory Evaluations in Biochemistry (Observed Values)   
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
                          
____________________________________________________________________________________________________________ _______________________  
                                          
                 Dose Group  
                       __________________________________________ _________________________  
             
         EGT0001442       EGT0001442       EGT0001442       EGT0001442                    
       Visit      5 mg           10 mg   20 mg           50 mg                  
      Day   Statistic          (N=xx)           (N=xx)           (N=xx)           (N=xx)            
____________________________________________________________________________________________________________ _______________________  
 
Albumin (G/L)     Screening   n                xx               xx               xx     xx   
(30 - 50)                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
       Day 0  n                xx               xx               xx     xx                    
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
       Day 1  n                xx               xx               xx     xx                    
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.x x   xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
                         ... 
         
  
ALT(SGPT)  (U/L)     Screening      n                xx               xx               xx     xx  
(8 – 54)                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                              Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
                                      
... 
___________________________________________________________________________________________________________ ________________________  
  
Note: Table will continue for other visit days 2, 3, 8, 15, 22, 23 and 43  and will continue for other lab parameter s. 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 57 of 100                                 
 
 
Similar tables:  
 
 
Table 14.3. 1.23 Clinical Laboratory Evaluations in Hematology  (Observed Values)   
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
 
 
Table 14.3. 1.24 Clinical Laboratory Evaluations in Urinalysis  (Observed Values)   
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 58 of 100  
Table 14.3. 1.25 Summary of Vital Signs  (Observed Values)  
Double -blind Segment   
 Double -blind Safety Analysis Set  
                          
____________________________________________________________________________________________________________ _______________________________  
                                          
           Treatment Group   
                           _______________________________________________________________________________  
                
            EGT0001442       EGT0001442       EGT0001442        EGT0001442                    
        Visit    Placebo    5 mg  10 mg     20 mg       50 mg                  
       Day   Statistic       (N=xx)           (N=xx)           (N=xx)           (N=xx)            (N=xx)                                            
____________________________________________________________________________________________________________ _______________________________  
 
Pulse (beats/minute)  Screening   n               xx               xx               xx     xx                xx      
                                Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                              Median          xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max        xx , xx          xx , xx          xx , xx     xx , xx           xx , xx   
       Day -2            n               xx               xx               xx     xx                xx      
                                Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                              Median          xx.x             xx.x             xx.x     xx.x              x x.x              
                             Min, Max        xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
       Day 1/Pre-dose     n               xx               xx               xx     xx                xx      
                                Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                              Median          xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max        xx , xx          xx , xx          xx , xx     xx , xx           xx , xx           
      Day 2/Pre-dose 
      Day 8   
      Day 15   
                     Day 22   
                     Day 29   
                     Day 35 
      Day 43                
  
Systolic BP (mmHg)   Screening   n               xx               xx               xx     xx                xx                                                          
      Mean ± SD       xx.x ± x .xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                              Median          xx.x             xx.x             xx.x     xx.x              xx.x                                         
      Min, Max        xx , xx          xx , xx          xx , xx     xx , xx           xx , xx                                            
... 
_____________________________________________________________________________________________________________________________ ______________  
  
Note: Table will continue for other vital signs . 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)   
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 59 of 100 Table 14.3. 1.26 Summary of Vital Signs in Change from Baseline  
Double -blind Segment   
 Double -blind Safety Analysis Set  
                          
____________________________________________________________________________________________________________ _______________________________  
                                          
           Treatment Group   
                           ___________ _____________________________________________________________________  
             
            EGT0001442       EGT0001442       EGT0001442        EGT0001442                    
         Visit    Placebo    5 mg  10 mg     20 mg       50 mg                  
        Day Statistic          (N=xx)           (N=xx)           (N=xx)           (N=xx)            (N=xx)                                            
___________________________________________________________________________________________________________ ______________ __________________  
 
Pulse (beats/minute)  Day 2 n                xx               xx               xx     xx                xx      
                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx 
                                 P-value*              x.xxxx     x.xxxx   x.xxxx     x.xxxx       x.xxxx 
 
        Day 8 n                xx               xx               xx     xx                xx      
                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
     P-value*              x.xxxx     x.xxxx   x.xxxx     x.xxxx       x.xxxx 
      
                         ... 
         
  
Systolic BP (mmHg)    Day 2      n                xx               xx               xx     xx                xx                                                          
     Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
     P-value*              x.xxxx     x.xxxx   x.xxxx     x.xxxx       x.xxxx           
                                      
... 
_____________________________________________________________________________________________________________________________ ______________  
  
Note: Baseline is defined as the l ast observed measurement prior to dosing on Day 1 at Visit 5. 
Note: *P -values are from paired t -test. 
Note: Table will continue for other days 8, 15, 22, 29, 35 and 43 an d will continue for other  vital signs.  
 
(Source: path \program name  Date /time of run: ddmmmyyyy:hh:mm)                                                                 
                                                               
 
 
 
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 60 of 100  
Table 14.3. 1.27 Summary of Vital Signs (Observed Values)   
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
                          
____________________________________________________________________________________________________________ _______________________  
                                          
                 Dose Group   
                          _____________________________________________________________________  
             
         EGT0001442       EGT0001442       EGT0001442       EGT0001442                    
       Visit     5 mg           10 mg          20 mg           50 mg                  
      Day  Statistic           (N=xx)           (N=xx)           (N=xx)           (N=xx)            
____________________________________________________________________________________________________________ _______________________  
 
Pulse (beats/minute)  Screening   n                xx               xx               xx     xx                     
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
       Day 0  n                xx               xx               xx     xx                    
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
       Day 1/Pre -dose     n                xx               xx               xx     xx                    
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
       Day 1/1 hr          
       Day 1/2 hr         
       Day 1/4 hr     
                      Day 1/8 hr          
       Day 2/Pre-dose                
                      Day 3/Pre-dose      
       Day 8              
                      Day 15    
                      Day 22 
                      Day 29 
                      Day 43         
  
Systolic BP (mmHg)      
___________________________________________________________________________________________________________ ________________________  
  
Note: Table will continue for other vital signs  
 
(Source: path \program name  Date /time of run: ddmmmyyyy:hh:mm)                                                                 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 61 of 100 Table 14.3. 1.28 Summary of 12-Lead ECG  (Observed Values)   
Double -blind Segment   
 Double -blind Safety Analysis Set  
                          
__________________ __________________________________________________________________________________________ _______________________________  
                                      
           Treatment Group   
                           __________________________________________________________________________________  
             
            EGT0001442       EGT0001442       EGT0001442        EGT0001442                    
        Visit     Placebo   5 mg  10 mg     20 mg       50 mg                  
       Day   Statistic        (N=xx)         (N=xx)           (N=xx)           (N=xx)            (N=xx)                                            
_________________________________________________________________________________________________ ___________ _______________________________  
 
PR Interval (ms)      Screening   n               xx               xx               xx     xx                xx      
                                Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                              Median          xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max        xx , xx          xx , xx          xx , xx     xx , xx           xx , xx   
       Day -2  n               xx               xx               xx     xx                xx      
                                Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                              Median          xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max        xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
       Day 1/Pre-dose n               xx               xx               xx     xx                xx      
                                Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                              Median          xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max        xx , xx          xx , xx          xx , xx     xx , xx           xx , xx           
       Day 2/Pre -dose 
                      Day 29         
  
QRS Interval (ms)     Screening      n               xx               xx               xx     xx                xx                                                          
      Mean ± SD       xx.x ± x.xx      xx.x ± x.xx      xx.x  ± x.xx   xx.x ± x.xx       xx.x ± x.xx       
                              Median          xx.x             xx.x             xx.x     xx.x              xx.x              
                              Min, Max        xx , xx          xx , xx          xx , xx     xx , xx           xx , xx           
                                      
... 
_____________________________________________________________________________________________________________________________ ______________  
  
Note: Table will continue for other ECGs. 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)   
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 62 of 100 Table 14.3. 1.29 Summary of 12 -Lead ECG in Change from Baseline  
Double -blind Segment   
 Double -blind Safety Analysis Set  
                          
____________________________________________________________________________________________________________ _______________________________  
                                          
           Treatment Group   
                           ___________________ ________________________________________________________________  
                   
            EGT0001442       EGT0001442       EGT0001442        EGT0001442                    
        Visit    Placebo    5 mg  10 mg     20 mg       50 mg                  
       Day       Statistic          (N=xx)           (N=xx)           (N=xx)           (N=xx)            (N=xx)                                            
______________________________________________________________________________________________________ _____________________________________  
 
PR Interval (ms)      Day 2 n                xx               xx               xx     xx                xx      
                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
                                 P-value*              x.xxxx     x.xxxx   x.xxxx     x.xxxx       x.xxxx 
 
       Day 8 n                xx               xx               xx     xx                xx      
                               Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                            Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
     P-value*              x.xxxx     x.xxxx   x.xxxx     x.xxxx       x.xxxx 
      
                         ... 
         
  
QRS Interval (ms)      Day 2     n                xx               xx               xx     xx                xx                                                          
     Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx       xx.x ± x.xx       
                             Median           xx.x             xx.x             xx.x     xx.x              xx.x              
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx           xx , xx  
     P-value*              x.xxxx     x.xxxx   x.xxxx     x.xxxx       x.xxxx           
                                      
... 
_____________________________________________________________________________________________________________________________ ______________  
  
Note: Baseline is d efined as the last observed measurement prior to dosing on Day 1 at Visit 5. 
Note: *P -values are from paired t -test. 
Note: Table will continue for other days 15, 22 and 29 and will continue for other ECGs.  
 
(Source: path \program name  Date/time of run: ddm mmyyyy:hh:mm)                                                                 
 
 
                                                                                                                           
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 63 of 100 Table 14.3. 1.30 Summary of 12-Lead ECG (Observed Values)   
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
                                                
____________________________________________________________________________________________________________ ____________ ___________  
                                          
                 Dose Group   
                      _______________________________________________ __________________________  
             
         EGT0001442       EGT0001442       EGT0001442       EGT0001442                    
       Visit     5 mg           10 mg          20 mg           50 mg                  
      Day   Statistic          (N=xx)           (N=xx)           (N=xx)           (N=xx)            
____________________________________________________________________________________________________________ _______________________  
 
Pulse (beats/minute)  Screening   n                xx               xx               xx     xx                     
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
       Day 0  n                xx               xx               xx     xx                    
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
       Day 1/Pre -dose n                xx               xx               xx     xx                    
                                Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                             Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
       Day 1/2 hr 
                      Day 2/Pre -dose 
                      Day 29         
  
Systolic BP (mmHg)    Screening   n                xx               xx               xx     xx                                                                        
      Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx    xx.x ± x.xx        
                              Median           xx.x             xx.x             xx.x     xx.x               
                              Min, Max         xx , xx          xx , xx          xx , xx     xx , xx            
                                      
... 
___________________________________________________________________________________________________________ ________________________  
  
Note: Table will continue for other ECGs. 
 
(Source: path \program name  Date/t ime of run: ddmmmyyyy:hh:mm)                                                                 
 
 
 
 
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 64 of 100 Table 14.3. 1.31 Summary of Fasting Plasma Glucose  by Visit  (Observed Values)   
Double -blind Segment   
 Double -blind Safety Analysis Set  
                          
____________________________________________________________________________________________________________ _______________________  
                                          
          Treatment Group   
             ___________________________________________________________________________________ _____ 
             
          EGT0001442       EGT0001442        EGT0001442        EGT0001442                    
Visit      Placebo    5 mg       10 mg      20 mg           50 mg                  
Day  Statistic          (N=xx)           (N=xx)           (N=xx)            (N=xx)            (N=xx)                                            
__________________________________________________________________________________ __________________________ _______________________  
 
Screening   n                xx               xx               xx    xx                xx                                                           
         Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx       xx.x ± x.xx       
   Median           xx.x             xx.x             xx.x      xx.x              xx.x              
   Min, Max         xx , xx          xx , xx          xx , xx      xx , xx           xx , xx  
  
Day -2  n                xx               xx               xx      xx                xx                                                           
   Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx       xx.x ± x.xx       
   Median           xx.x             xx.x             xx.x      xx.x              xx.x              
   Min, Max         xx , xx          xx , xx          xx , xx        xx , xx           xx , xx  
 
Day 1  n                xx               xx               xx      xx                xx                                                           
   Mean ± SD        xx.x ± x.xx      xx.x ± x.xx      xx.x ± x.xx     xx.x ± x.xx       xx.x ± x.xx       
   Median           xx.x             xx.x             xx.x      xx.x              xx.x              
   Min, Max         xx , xx          xx , xx          xx , xx      xx , xx           xx , xx           
... 
         
  
___________________________________________________________________________________________________________ ________________________  
  
Note: Table will continue for Days 2,8,15,22, 27,29,35,41 and 43. 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 65 of 100 Table 14.3. 1.32 Summary of Concomitant Medication  
Double -blind Segment   
 Double -blind Safety Analysis Set  
             
_______________________________________________________________________________________________________ ______________________  
  
                                           Treatment  Group  
     ______________________________________________________________________ _______________ __ 
 
       EGT0001442       EGT0001442       EGT0001442       EGT0001442                    
     Placebo  5 mg           10 mg            20 mg      50 mg                  
Preferred Medication Term   (N=xx)         (N=xx)           (N=xx)           (N=xx)    (N=xx)                             
_________________________________________________________________________________________ _____________ _______________________                       
Any Medication      xx ( xx.x%) xx ( xx.x%)       xx ( xx.x%)    xx ( xx.x %)  xx ( xx.x%)     
            
ConMed 1       xx ( xx.x%)  xx ( xx.x%)       xx ( xx.x%)    xx ( xx.x%)   xx ( xx.x%)     
 
ConMed 2       xx ( xx.x%)  xx ( xx.x%)       xx ( xx.x%)    xx ( xx.x%)   xx ( xx.x%)     
 
ConMed 3       xx ( xx.x%)  xx ( xx.x%)       xx ( xx.x%)    xx ( xx.x%)   xx ( xx.x%)     
 
ConMed 4       xx ( xx.x%)  xx ( xx.x%)       xx ( xx.x%)    xx ( xx.x%)   xx ( xx.x%)     
     
  
 
______________________________________________________________________________________________________ _______________________  
Note: A subject is counted only once per concomitant medication.  
N: Number of subjects exposed                     
%: Percentage is based N 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                            
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001          Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 66 of 100  
Table 14.3. 1.33 Summary of Concomitant Medication  
Dose Escalation Segment  
 Dose Escalation Safety Analysis Set  
             
________ _______________________________________________________________________________________________ ______________________  
  
                                         Dose Group  
        ______________________________________ ____________________________  
 
     EGT0001442      EGT0001442       EGT0001442      EGT0001442                    
     5 mg         10 mg            20 mg           50 mg                  
Preferred Medication Term   (N=xx)         (N=xx)           (N=xx)          (N=xx)                                      
________________________________________________________________________________________________________ _____________________                     
Any Medication      xx ( xx.x%)  xx ( xx.x%)       xx ( xx.x%)    xx ( xx.x%)       
            
ConMed 1      xx ( xx.x%)  xx ( xx.x%)       xx ( xx.x%)    xx ( xx.x%)    
 
ConMed 2       xx ( xx.x%)  xx ( xx.x%)       xx ( xx.x%)    xx ( xx.x%)    
 
ConMed 3       xx ( xx.x%)  xx ( xx.x%)       xx ( xx.x%)    xx ( xx.x%)    
 
ConMed 4       xx ( xx.x%)  xx ( xx.x%)        xx ( xx.x%)    xx ( xx.x%)    
     
  
 
______________________________________________________________________________________________________ _______________________  
Note: A subject is counted only once per concomitant medication.  
N: Number of subjects in the specified group  
%: Percentage is based N 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                            
 
 
Theracos, Inc. Protocol No. THR -1442 -C-402 
Cetero Research Protocol No. CTJK09001  ______________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17-May-2010                     Page 67 of 100    
 
 
 
Summary Listings  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 68 of 100  
 
Listing 16.2.1 Subject  Disposition  
 
________________________________________________________________________________________________________________ ___________________  
                                                               
                   Date       
Study         Subject  Last/       Termination            Termination                     
Segment  Treatment         Center  Number  Contact        Status              Reason         
______________________________________________________________________________________________________ __________ ___________________  
Double-blind Placebo       02 02141    ddmmmyyyy      Completed  
           02142    ddmmmyyyy      Discontinued due to adverse event  xxxxxxxxxxxxxxxxxxxx  
               ... 
                  ...                               
 
   EGT0001442 5 mg 
 
   EGT0001442 10 mg 
 
   EGT0001442 20 mg 
 
   EGT0001442 50 mg 
 
 
Dose Escalation   EGT0001442 5 mg       01  003     ddmmmyyyy      Completed  
               ...  
      ... 
   EGT0001442 10 mg 
 
   EGT0001442 20 mg 
 
   EGT0001442 50 mg 
 
 
 
 
________________________________________________________________________________________________________________ ___________________  
 
 
 
(Source: path \program name  Date /time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 69 of 100 Listing 16.2.2 Protocol Deviation s 
 
________________________________________________________________________________________________________________ _______________  
     
Study                     Subject Deviation        Deviation  Description of        Deviation  
Segment          Treatment      Center Number   Date /Time  Page ID      Category  Deviation    Major/minor  
________________________________________________________________________________________________________________ _______________  
Double-blind      Placebo        02    02141   ddmmmyyyy/hhmm  EX0012      DOSING xxxxxxxxxxxxx           Minor 
       ... 
      ... 
 
 
       EGT0001442 5 mg 
 
               EGT0001442 10 mg 
 
               EGT0001442 20 mg 
 
               EGT0001442 50 mg 
 
                   
Dose Escalation   EGT0001442 5 mg    01  003   ddmmmyyyy/hhmm  EX0012      DOSING xxxxxxxxxxxxxx    NA    
 
   EGT0001442 10 mg 
 
   EGT0001442 20 mg 
 
   EGT0001442 50 mg 
         
               
 
________________________________________________________________________________________________________________ ______________  
 
 
(Source: path \program name  Date /time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 70 of 100 Listing 16.2.3 Subject s Excluded from the Efficacy Analysis  (Double -blind Segment ) 
 
_____________________________________________________________________________________________________________ ________________  
  
     Subject                 
Treatment   Center  Number      Safety Population  ITT Population   PP Population  
____________________ _________________________________________________________________________________________ ________________  
Placebo  02  02141     Yes   No  No 
               
 
 
 
 
EGT0001442 5 mg 
 
EGT0001442 10 mg 
 
EGT0001442 20 mg 
 
EGT0001442 50 mg 
 
 
 
_____________________________________________________________________________________________________________ ________________  
 
 
 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)      
 
                                                            
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 71 of 100 Listing 16.2.4.1 Demographics  
 
_____________________________________________________________________________________________________________ ________________________  
  
Study     Subject    Date of    Age        Height    Weight   BMI   
Segment  Treatment    Center Number     Birth   (yrs)   G ender   Race   Ethnicity    (cm)      (kg)    (kg/m^2)     
__________________________________________________________________________________________ ______________ _____________________________  
Double-blind      Placebo      02  02141    ddmmmyyyy    xx      Male    White  Hispanic  or Latino   xxx    xxx.x     xxx.x 
               
                     ... 
 
                              ... 
 
   EGT0001442 5 mg 
 
   EGT0001442 10 mg 
 
   EGT0001442 20 mg 
 
   EGT0001442 50 mg 
 
 
Dose Escalation   EGT0001442 5 mg        
 
   EGT0001442 10 mg 
 
   EGT0001442 20 mg 
 
   EGT0001442 50 mg 
 
 
_____________________________________________________________________________________________________________ ______________________ _ 
 
 
(Source: path \program name  Date /time of run: ddmmmyyyy:hh:mm)                                                                 
 
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 72 of 100  
Listing 16.2.4. 2 Medical History  
 
________________________________________________________________________________________________________________ _________ __________  
                                                                     
                  
Study                                 Subject  Seq.  Body                 Medical history      Start                 Stop     
Segment          Treatment   Center   Number   No.   System            Findings       Date     Ongoing     Date    
________________________________________________________________________________________________________________ ___________________  
Double-blind     Placebo      02      02141     1    Eyes, Ears, Nose, Throat   NORMAL 
            2    Neurologica l           OCCASIONAL HEADACHES UNKUNK1989    Yes 
            3    Cardiovascular           HIGH CHOLESTEROL     UNKUNK2007    Yes 
            4    Skin            BALANITIS      21DEC2009      29DEC2009  
      
       ...   
                                       ...            
       ... 
    
   EGT0001442 5 mg 
 
   EGT0001442 10 mg 
 
   EGT0001442 20 mg 
  
   EGT0001442 50 mg 
 
 
Dose Escalation   EGT0001442 5 mg        
 
   EGT0001442 10 mg 
 
   EGT0001442 20 mg 
 
   EGT0001442 50 mg 
 
________________________________________________________________________________________________________________ __________________  
 
(Source: path \program name  Date /time of run: ddmmmyyyy:hh:mm)   
 
 
 
                                                               
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 73 of 100 Listing 16.2 .4.3 Prior and Concomitant Medication  
 
______________________________________________________________________________________________________ ______________________________ _____ 
                  
                      ATC Classification            
Study                            Subject    WHO Drug Name     Start/Stop          Drug             Frequency  Route of          
Segment        Treatment  Center Number       Medication Name   Date       Ongoing  Strength  Units  of dose   Administration Indication     
_____________________________________________________________________________________________________________________________ __________ __ 
               
Double-blind      Placebo   02      02141   xxxxxxxx xxxxxxxxxx    ddmmmyyyy/  No      xx        mg     bid       PO           xxxxxxxxx      
           xxxxxxxxxxxxxxxxx     ddmmmyyy  
                                               xxxxxxxxxxxxxx  
     ... 
 
 
 
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation  EGT0001442 5 mg  
 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
__________________________________________________________________________________________________________ _______________________________  
 
 
 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)  
                                                                                
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 74 of 100 Listing 16.2.4. 4 Inclusion/Exclusion Criteria and Exceptions  
 
________________________________________________________________________________________________________________ ___________________  
 
          Were all                        
          Inclusion/               Inclusion/Exclusion      Was a  Date 
Study                   Subject  Exclusion      Consent    Washout    ___________________       Waiver  of Waiver  
Segment       Treatment  Center  Number  Criteria met?    Date Type*      Category        No.      Granted?  Granted 
________________________________________________________________________________________________________________ ___________________  
 
Double-blind     Placebo    02    02141       Yes     ddmmmyyyy   1 
                          02142       No     ddmmmyyyy   2           Includion     2        Yes  ddmmmyyyy  
   
      
 
 
      
 
   EGT0001442 5 mg 
 
   EGT0001442 10 mg 
 
   EGT0001442 20 mg 
 
   EGT0001442 50 mg 
 
 
Dose Escalation   EGT0001442 5 mg        
 
   EGT0001442 10 mg 
 
   EGT0001442 20 mg 
 
   EGT0001442 50 mg 
 
 
________________________________________________________________________________________________________________ ___________________  
Note: *Washout Type: 1 = Diabetic Med  Discontin ued, 2 = Diabetic Med Naïve   
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)  
 
 
 
                                            
 
 
 
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 75 of 100 Listing 16.2.4. 5 Urine Drug Screen  
 
________________________________________________________________________________________________________________ _____________  
 
               
Study                      Subject   Visit         Test      Test              
Segment       Treatment   Center    Number     Day    Date/Time         Name     Results 
________________________________________________________________________________________________________________ _____________  
 
Double-blind     Placebo      02  02141  Screening ddmmmyyyy /hhmm   Amphetamines    Negative          
                Barbiturates    Negative  
                Cocaine metabolites   Negative  
                Opiates     Negative  
                Benzodiazepines   Negative  
                Cannabinoids    Negative  
                Cotinine     Negative  
    
           Day 0    ddmmmyyyy/hhmm     Amphetamines    Negative   
                Barbiturates    Negative  
                Cocaine metabolites   Negative  
                Opiates     Negative  
                Benzodiazepines   Negative  
                Cannabinoids    Negative  
                Cotinine     Negative  
                                ... 
      
 
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation   EGT0001442 5 mg        
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
________________________________________________________________________________________________________________ _____________  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)  
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 76 of 100  
Listing 16.2.5  Study Drug Administration  
                                                                     
________________________________________________________________________________________________________________ _____________  
 
         Did subjec t fast 
Study     Subject  Dose 10 hours   Dose     Dose         
Segment  Treatment    Center  Number   Day Prior to dose?   Date/Time   Status   
________________________________________________________________________________________________________________ _____________  
 
Double-blind     Placebo      02 02141         1   Yes   ddmmmyyyy /hhmm  Dosed 
        2   Yes   ddmmmyyyy/hhmm   Dosed 
        3   Yes   ddmmmyyyy/hhmm   Dosed 
        4      ddmmmyyyy/hhmm   Dosed 
        5      ddmmmyyyy/hhmm   Dosed 
        6      ddmmmyyyy/hhmm   Dosed 
        7      ddmmmyyyy/hhmm   Dosed 
                                    ... 
  
        27      ddmmmyyyy/hhmm   Dosed 
        28      ddmmmyyyy/hhmm   Dosed 
       
                                 
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation   EGT0001442 5 mg        
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
_______________________________________________________________________________________________________________ ______________  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                  
 
 
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 77 of 100  
Listing 16.2.6.1 Fasting Plasma Glucose (mg/dL )  
                                                                     
______________________________________________________________________________________________________________ _______________  
                                                                 
                                                                          Observed FPG                           
Study                  Subject   Visit   Test        Results          
Segment   Treatment         Center  Number   Day         Repeat  Date/Time         (mg/dL)           
________________________________________________________________________________________________________________ _____________  
Double-blind     Placebo            02 02141  Screening    ddmmmyyyy/ hh:mm     xxxx.x 
         Day -2   ddmmmyyyy/ hh:mm     xxxx.x 
         Day 1           ddmmmyyyy/ hh:mm     xxxx.x        
         Day 2           ddmmmyyyy/ hh:mm     xxxx.x      
         Day 8           ddmmmyyyy/ hh:mm     xxxx.x      
         Day 15           ddmmmyyyy/ hh:mm     xxxx.x      
         Day 22          ddmmmyyyy/ hh:mm     xxxx.x     
         Day 29    ddmmmyyyy/ hh:mm     xxxx.x     
         Day 35    ddmmmyyyy/ hh:mm     xxxx.x 
         Day 43    ddmmmyyyy/ hh:mm     xxxx.x      
   ... 
       
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation   EGT0001442 5 mg    01    003      Screening    ddmmmyyyy/hh:mm     xxxx.x 
         Day 0   ddmmmyyyy/hh:mm     xxxx.x 
         Day 1     ddmmmyyyy/hh:mm     xxxx.x     
         Day 2     ddmmmyyyy/hh:mm     xxxx.x     
         Day 3          ddmmmyyyy/hh:mm     xxxx.x     
         Day 8           ddmmmyyyy/hh:mm     xxxx.x    
         Day 15           ddmmmyyyy/hh:mm     xxxx.x    
         Day 22           ddmmmyyyy/hh:mm     xxxx.x     
         Day 29          ddmmmyyyy/hh:mm     xxxx.x     
         Day 43   ddmmmyyyy/hh:mm     xxxx.x      
                  
   ...                                     
 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
_______________________________________________________________________________________________________________ ______________  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                  
 
                                                                    
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 78 of 100  
Listing 16.2.6.2  Weight  
 
__________________________________________________________________________________________________________ ___________________  
                          
Study       Subject        Visit     Visit  Weight         
Segment  Treatment    Center Number    Day       Date    (kg)          
__________________________________________________________________________________________________________ ___________________  
 
Double-blind      Placebo        02 02141       Screening          ddmmmyyyy   xx.x            
          Day -2     ddmmmyyyy   xx.x    
          Day 1   ddmmmyyyy   xx.x    
         Day 8       ddmmmyyyy  xx.x    
          Day 15     ddmmmyyyy  xx.x    
          Day 22     ddmmmyyyy  xx.x    
          Day 29     ddmmmyyyy  xx.x    
          Day 35     ddmmmyyyy  xx.x  
         Day 43     ddmmmyyyy  xx.x   
                ... 
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation   EGT0001442 5 mg      01 003      Screening         ddmmmyyyy   xx.x           
          Day 0      ddmmmyyyy   xx.x    
          Day 1   ddmmmyyyy   xx.x    
         Day 3       ddmmmyyyy  xx.x    
          Day 15     ddmmmyyyy  xx.x    
          Day 22     ddmmmyyyy  xx.x    
          Day 29     ddmmmyyyy  xx.x    
          Day 43     ddmmmyyyy  xx.x    
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
 
___________________________________________________________________________________________________________ __________________  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)  
                                                                         
 
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 79 of 100 Listing 16.2.6. 3 Glycated Hemoglobin A 1 (HbA1c)  (%)  
                                                                     
________________________________________________________ ________________________________________________________ ______________  
                                                                       
                                                                            Observed HbA1c                       
Study          Subject   Visit                    Test       Results        
Segment  Treatment       Center  Number      Day      Repeat  Date/Time         (%)    
________________________________________________________________________________________________________________ ______________  
Double-blind     Placebo          02 02141      Screening        ddmmmyyyy/hh:mm     xx.x 
         Day 1   ddmmmyyyy/hh:mm     xx.x        
         Day 29           ddmmmyyyy/hh:mm     xx.x      
        
             
 
          
   ...       
                                 
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation   EGT0001442 5 mg        
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
_______________________________________________________________________________________________________________ _______________  
  
 
(Source: path \program name  Date/time of run: ddmmmyy yy:hh:mm)                                  
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 80 of 100 Listing 16.2.6.4 24 h UGE ( g/day) 
                                                                     
________________________________________________________________________________________________________________ ___________________  
                                                                       
                                                                           Observed UGE                      
Study              Subject   Visit   Test             Results         
Segment   Treatment       Center     Number     Day        Repeat  Date/Time            (g/day)           
________________________________________________________________________________________________________________ ___________________  
Double-blind     Placebo          02    02141 Screening       ddmmmyyyy/hh:mm     xxxx.x 
         Day 1   ddmmmyyyy/hh:mm     xxxx.x       
         Day 29           ddmmmyyyy/hh:mm     xxxx.x     
        
             
 
          
   ...       
                                 
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation   EGT0001442 5 mg        
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
_______________________________________________________________________________________________________________ ____________________  
 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                  
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 81 of 100  
Listing 16.2. 6.5 Blood (PK) Sample Collection  (Dose Escalation Segment)  
                                                                                                                                          
_________________________________________________________________________________________________________ ______________________  
                                                                                                     
          Subject  Sample      Study         Scheduled      Scheduled     Actual      Reason for              
Treatment          Center Number   Number      Hour          Date            Time          Time        Deviation               
_________________________________________________________________________________________________________ ______________________  
                                                                                                                                          
EGT0001442 5 mg     01      003   1      PRE-DOSE 10Dec2009                 0619  
       2     0.5 H  10Dec2009                 0830  
       3     1 H  10Dec2009                 hhmm  
       4     2 H  10Dec2009                 hhmm                                                                                                                                                                                                                                                                                                                                                                                                      
       5     3 H  10Dec2009                 hhmm                                                                                                                                                                                                                                                                                                                                                                                                      
       6     4 H  10Dec2009                 hhmm                                                                                                                                                                                                                                                                                                                                                                                                      
       7     6 H  10Dec2009                 hhmm                                                                                                                                                                                                                                                                                                                                                                                                      
       8     8 H  10Dec2009                 hhmm                                                                                                                                                                                                                                                                                                                                                                                                      
       9     10 H  10Dec2009                 hhmm                                                                                                                                                                                                                                                                                                                                                                                                      
       10     12 H  10Dec2009                 hhmm                                                                                                                                                                                                                                                                                                                                                                                                      
       11     24 H  10Dec2009                 hhmm  
       12     48 H  10Dec2009                 hhmm                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                  
 
 
 
 
 
EGT0001442 10 mg 
 
EGT0001442 20 mg 
 
EGT0001442 50 mg 
 
________________________________________________________________________________________________________________ _______________  
Note: Scheduled time is only entered if differ from actual time.  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)  
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 82 of 100  
Listing 16.2.6.6 Post Prandial Blood Glucose (mg/dL ) (Dose Escalation  Segment)  
                                                                     
________________________________________________________________________________________________________________ ___________________  
                      Change from                                                                       
                                                                         Observed   Pre-meal to                     
                Subject Visit  Time                      Test          Results   Post-meal     AUC 
Treatment         Center Number  Day    Point              Date/Time         Name        (mg/dL)   (mg/dL)      (mg.h/dL)  
________________________________________________________________________________________________________________ ___________________  
EGT0001442 5 mg 01     003 Day 0 Prior to Breakfast  09Dec2009/0845    BLOOD GLUCOSE  220 
        2 Hours Post Breakfast  09Dec2009/ 1107    BLOOD GLUCOSE  291  71 
       Prior to Lunch   09Dec2009/ 1255    BLOOD GLUCOSE  176 
       2 Hours Post Lunch  09Dec2009/ 1517    BLOOD GLUCOSE  243  67 
       Prior to Dinner 09Dec2009/ 1755    BLOOD GLUCOSE  184 
       2 Hours Post Dinner  09Dec2009/ 2018    BLOOD GLUCOSE  241  57 
       10:00 PM   09Dec2009/ 2245    BLOOD GLUCOSE  220                xxxx.x 
 
     Day 2 Prior to Breakfast  11Dec2009/0845    BLOOD GLUCOSE  220 
      2 Hours Post Breakfast  11Dec2009/1107    BLOOD GLUCOSE  272  52 
      Prior to Lunch   11Dec2009/1255    BLOOD GLUCOSE  176 
      2 Hours Post Lunch  11Dec2009/1517    BLOOD GLUCOSE  243  67 
      Prior to Dinner  11Dec2009/1755    BLOOD GLUCOSE  184 
      2 Hours Post Dinner  11Dec2009/2018    BLOOD GLUCOSE  243  59 
      10:00 PM   11Dec2009/2245    BLOOD GLUCOSE  220                xxxx.x   
          
   ... 
       
                                 
 
EGT0001442 10 mg 
 
EGT0001442 20 mg 
 
EGT0001442 50 mg 
 
_______________________________________________________________________________________________________________ ____________________  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                  
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 83 of 100 Listing 16.2.7.1 Treatment Emergent Adverse Events  
 
_______________________________________________________________________________________________________________ _______________________  
                                                                                                                                                                                                                          
                                            System Organ Class                                        Relationship                                
Study                    Subject  AE    Preferred Term    Onset/Resolution                to       Action              
Segment     Treatment  Center Number   No.     Verbatim Term    Date     Time   Serious?*  Severity#  Study Drug¹   Taken²   Outcome³  
_______________________________________________________________________________________________________________ _______________________  
                                                                                                                                                                                                                             
Double-blind  Placebo     02    02141  1     xxxxxxxxxxxxxxx   ddmmmyyyy hh:mm/    0          1          2            0      1     
                         xxxxxxxxxxxxx     ddmmmyyyy hh:mm 
                       xxxxxxxxxxx  
     ... 
 
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation   EGT0001442 5 mg        
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
_______________________________________________________________________________________________________________ ______________________  
                                                                     
Note: * Serious?: 1 = Yes,  2 = No                                                                                                                 
      # Severity: 1 = Mild, 2 = Moderate , 3 = Severe.                                                                                                          
      ¹ Relationship to study drug: 1 = Yes, 2 = No                                                               
      ² Action taken: 1  = None, 2 = Medication  Administered , 3 = Non-Drug Therapy, 4 = Hospitalization, 5 = Discontinu ation From Study ,  
                6 = Other.                                       
      ³ Outcome: 1= R esolved,  2 = Continuing with Treatment,  4 = Continuing w ithout Treatment, 10 = Death.                        
  
Sorting by: Study segment, Treatment, Center, Subject, Start Date, Start Time, End Date, End Time  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)  
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 84 of 100  
Similar Listings:                                                                 
 
 
Listing 16.2.7 .2 Drug -related Treatment Emergent Adverse Events  
 
Listing 16.2.7 .3 Serious T reatment Emergent Adverse Events  
  
Listing 16.2.7 .4 Treatment Emergent Adverse Events Leading to Study Discontinuation  
 
Listing 16.2.7 .5 Cardiovascular  Treatment Emergent Adverse Events  
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 85 of 100 Listing 16.2.7 .6 Pre-treatment Adverse Events  
 
_______________________________________________________________________________________________________________ ____________________  
                                                                                                                                                                                                                          
                                          System Organ Class                                        Relationship                                
Study                   Subject  AE    Preferred Term    Onset/ Resolution                             to       Action              
Segment         Center    Number   No.     Verbatim Term   Date     Time    Serious?*  Severity#  Study Drug¹   Taken²   Outcome³  
_______________________________________________________________________________________________________________ _____________ _______ 
                                                                                                                                                                                                                             
Double-blind      02       02141     1     xxxxxxxxxxxxxxx   ddmmmyyyy hh:mm/    0          1          2            0      1     
                         xxxxxxxxxxxxx    ddmmmyyyy hh:mm 
                       xxxxxxxxxxx  
     ... 
 
    
    
    
    
 
Dose Escalation    
    
   
 
_______________________________________________________________________________________________________________ ____________________  
                                                                     
Note:  
    * Serious?: 1 = Yes,  2 = No                                                                                                                 
      # Severity: 1 = Mild, 2 = Moderate, 3 = Severe.                                                                                                          
      ¹ Relationship to study drug: 1 = Yes, 2 = No                                                               
      ² Action taken: 1 = None, 2 = Medication  Administered , 3 = Non-Drug Therapy, 4 = Hospitalization, 5 = Discontinu ation From Study ,  
                6 = Other.                                       
      ³ Outcome: 1= R esolved,  2 = Continuing with Treatment,  4 = Continuing without Treatment, 10 = Death.                        
  
Sorting by: Study segment, Washout type , Center, Subject, Start Date, Start Time, End Date, End Time  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)  
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 86 of 100 Listing 16.2.7 .7 Adverse Events  during Washout Period  
 
_______________________________________________________________________________________________________________ ________________________  
                                                                                                                                                                                                                          
                                            System Organ Class                                        Relationship                                
Study        Washout       Subject  AE    Preferred Term    Onset/ Resolution                to       Action              
Segment       Type+  Center Number   No.     Verbatim Term   Date     Time    Serious?*  Severity#  Study Drug¹   Taken²   Outcome³  
_______________________________________________________________________________________________________________ ________________________  
                                                                                                                                                                                                                             
Double-blind     1      02    02141    1     xxxxx xxxxxxxxxx   ddmmmyyyy hh:mm/    0          1          2            0      1     
                         xxxxxxxxxxxxx     ddmmmyyyy hh:mm 
                       xxxxxxxxxxx  
     ... 
   
 
Dose Escalation    
 
_______________________________________________________________________________________________________________ ________________________  
                                                                     
Note: + Washout type: 1=  Diabetic Med Discontinued , 2= Diabetic Med Naive 
    * Serious?: 1 = Yes,  2 = No                                                                                                                 
      # Severity: 1 = Mild, 2 = Moderate, 3 = Severe.                                                                                                          
      ¹ Relationship to study drug: 1 = Yes, 2 = No                                                               
      ² Action taken: 1 = None, 2 = Medication  Administered , 3 = Non-Drug Therapy, 4 = Hospitalization, 5 = Discontinu ation From Study ,  
                6 = Other.                                       
      ³ Outcome: 1= R esolved,  2 = Continuing with Treatment,  4 = Continuing without Treatment, 10 = Death.                        
  
Sorting by: Study segment, Washout type , Center, Subject, Start Date, Start Time, End Date, End Time  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)  
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 87 of 100 Listing 16.2. 8.1 Clinical Laboratory Test Results  in Biochemistry  
 
 
________________________________________________________________________________________________________________ _______________________  
                                                                                     
                                                                                      ____________ SI Unit____________               
                                                                        Lab                                 
Study                               Subject Age/   Visit        --------------   Lab     Test         Normal    
Segment       Treatment   Center  Number  Gender Day  Repeat  Date    Time    Test    Results Unit Range     Flag *  Comments  
________________________________________________________________________________________________________________ _______________________  
Double-blind     Placebo     02     02141   36/M    Screening    ddmmmyyyy hh:mm  Albumin   xx    xx   xx-xx   L(NCS)   xxxxxxxxx  
                                                Calcium    xx    xx   xx-xx    
                                                                                     Creatinine xx    xx   xx-xx    
             
                                                                                       ... 
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation  EGT0001442 5 mg  
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
________________________________________________________________________________________________________________ _______________________  
 
 Note: * Flag: L = Low, H = High , NCS = Not clinical significance, CS = Clinical significance  
 
Table will continue for other biochemistry lab tests.  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)                                                                 
 
  
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 88 of 100 Similar listings:  
 
Listing 16.2. 8.2 Clinical Laboratory Test Results in Hematology   
 
Listing 16.2. 8.3 Clinical Laboratory Test Results in Urinalysis  
 
 
 
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 89 of 100 Listing 16.2. 8.4 Vital Signs  
 
_____________________________________________________________________________________________________________________________ _____________  
                         
                     Heart    Systolic    Diastolic  Respiratory   
Study                   Subject  Visit         Seated for    Rate      BP         BP    Rate         Temperature  
Segment        Treatment  Center  Number   Day         5 minutes?   (BPM)     (mmHg)     (mmHg)     (breaths/min)  (ºC)   
_____________________________________________________________________________________________________________________________ _____________  
 
Double-blind     Placebo     02    02141   Screening           Yes        xxx        xxx   xxx      xx.x          xx.x  
        Day -2              Yes        xxx        xxx   xxx      xx.x   xx.x 
        Day 1/Pre-dose      Yes        xxx        xxx   xxx      xx.x   xx.x 
        Day 2/Pre-dose      Yes        xxx        xxx   xxx      xx.x   xx.x 
        Day 8           Yes        xxx        xxx   xxx      xx.x   xx.x 
        Day 15        Yes        xxx        xxx   xxx      xx.x   xx.x 
        Day 22        Yes        xxx        xxx   xxx      xx.x   xx.x 
        Day 29        Yes        xxx        xxx   xxx      xx.x   xx.x 
        Day 35        Yes        xxx        xxx   xxx      xx.x   xx.x 
       Day 43        Yes        xxx        xxx   xxx      xx.x   xx.x 
 
             ...   
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation  EGT0001442 5 mg  01  003   Screening          Yes         xxx        xxx   xxx      xx.x          xx.x 
                     Day 0           Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 1/Pre -dose     Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 1/1 hr         Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 1/2 hr         Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 1/4 hr         Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 1/8 hr         Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 2/Pre-dose     Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 3/Pre-dose     Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 8           Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 15       Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 22       Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 29       Yes         xxx        xxx   xxx      xx.x          xx.x 
          Day 43         Yes         xxx        xxx   xxx      xx.x          xx.x 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
_____________________________________________________________________________________________________________________________ ______________  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)  
                                                                         
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 90 of 100  
Listing 16.2. 8.5 12-Lead ECG  
 
_____________________________________________________________________________________________________________________________ _____________  
 
           Ventri-   
                        cular   PR        QRS      QT       QTc     ECG                   
Study                    Subject Visit      Rate   Interval Interval  Interval Interval Findings     Repeat ECG 
Segment   Treatment  Center  Number  Day      (BPM)    (ms)     (ms)     (ms)     (ms)    (NCS/CS)    Status Description  
_____________________________________________________________________________________________________________________________ _____________  
 
Double-blind      Placebo      02   02141  Screening         xxx    xxx      xxx      xxx      xxx     Normal        
        Day -2            xxx    xxx      xxx      xxx      xxx     Abnormal(NCS) N R  xxxxxxx      
        Day 1/Pre -dose    xxx    xxx      xxx      xxx      xxx     Normal      
        Day 2/Pre -dose    xxx    xxx      xxx      xxx      xxx     Normal       
        Day 29      xxx    xxx      xxx      xxx      xxx     Normal      
               ... 
   
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation  EGT0001442 5 mg  01    003    Screening        xxx    xxx      xxx      xxx      xxx     Normal        
           Day 0         xxx    xxx      xxx      xxx      xxx     Normal      
           Day 1/Pre -dose   xxx    xxx      xxx      xxx      xxx     Normal      
           Day 1/ 2 hr      xxx    xxx      xxx      xxx      xxx     Normal      
           Day 2/Pre -dose   xxx    xxx      xxx      xxx      xxx     Normal      
           Day 29     xxx    xxx      xxx      xxx      xxx     Normal      
 
                ... 
 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
_____________________________________________________________________________________________________________________________ ______________  
 
Note: 
CS  = Clinically Significant  
NCS = Not Clinically Significant  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)  
                                                                         
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 91 of 100  
Listing 16.2. 8.6 Self Monitored Blood Glucose ( SMBG)  
 
__________________________________________________________________________________________________________ ___________________  
                          
Study      Subject        Visit            Results 
Segment  Treatment  Center  Number    Day    Date Time      (mg/dL)    
__________________________________________________________________________________________________________________ ___________  
 
Double-blind      Placebo    02  02141       DAY-14  ddmmmyyyy   HHMM     xxx 
        DAY-13  ddmmmyyyy    HHMM     xxx 
        DAY-12  ddmmmyyyy   HHMM     xxx 
        DAY-11  ddmmmyyyy   HHMM     xxx 
        DAY-10  ddmmmyyyy   HHMM     xxx 
        DAY-9  ddmmmyyyy   HHMM     xxx 
        DAY-8  ddmmmyyyy   HHMM     xxx 
        DAY-7  ddmmmyyyy   HHMM     xxx 
        DAY-6  ddmmmyyyy   HHMM     xxx 
        DAY-5  ddmmmyyyy   HHMM     xxx 
        DAY-4  ddmmmyyyy   HHMM     xxx 
        DAY-3  ddmmmyyyy   HHMM     xxx 
        DAY-2  ddmmmyyyy   HHMM     xxx 
        DAY-1  ddmmmyyyy   HHMM     xxx 
        DAY 0  ddmmmyyyy   HHMM     xxx 
        DAY 1  ddmmmyyyy   HHMM     xxx 
        DAY 2  ddmmmyyyy   UNK     xxx 
        DAY 3  ddmmmyyyy   UNK     xxx 
     
                                    ... 
                                  Day 43   ddmmmyyyy   HHMM     xxx 
               ... 
   
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation  EGT0001442 5 mg  
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
___________________________________________________________________________________________________________ __________________  
 
Note: SMBG are measured daily after washout starts till the last termination visit.  
Note: table will continue for other Days.  
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)  
                                                                        
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001           Page X of N  ___________________________________________________________________________________________  
 
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 92 of 100  
Listing 16.2. 8.7 Physical Examination  
 
________________________________________________________________________________________________________________ _____________  
  
              Change                                                                    
Study                     Subject    Visit      from Body  Examination    
Segment  Treatment    Center   Number     Day      Previous System   Finding     
_____________________________________________________________________________________________________________________________  
 
Double-blind      Placebo       02  02141    Screening    Skin  Sunburn left hand (peeling skin)  
          Head   Normal   
          Eyes   Normal 
             Ears   Normal 
          Nose   Normal 
          Throat   Normal       
          Neck   Normal 
          Thyroid   Normal  
          Lungs   Normal 
          Heart   Normal 
          Abdomen   Normal  
          Lymph Nodes   Normal 
          Extremities   Normal 
 
         Day -2  Yes Skin   Normal 
 
    ... 
                                                    
   EGT0001442 5 mg 
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
 
Dose Escalation  EGT0001442 5 mg  
   EGT0001442 10 mg 
   EGT0001442 20 mg 
   EGT0001442 50 mg 
________________________________________________________________________________________________________________ _____________  
 
Note: tab le will continue for Days 1,8,15,22, 29,35 and 43 for double -blind segment . 
      table will continue for screening, Days  0,1,3,8,15,22, 29 and 43 for dose escalation segment . 
 
 
(Source: path \program name  Date/time of run: ddmmmyyyy:hh:mm)     
    
                                                     
 
Theracos, Inc. Protocol No. THR-1442 -C-402 
Cetero Research Protocol No. CTJK09001  
______________________________________________________________  
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 93 of 100  
 
 
 
 
 
 
 
 
Figures  
 
 
 
 
 
 
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001              
_________________________________________________________________________________________  
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 94 of 100  
 
Figure 14.2.1 Fasting Plasma Glucose (mean± SE)  - Double -blind Segment  
 
 
 
 
 
 
 
 
Time (Day) -2 1 2  8  15  22  29  35  43Fasting Plasma Glucose (mg/dL)
02004006008001000
Placebo
EGT0001442     5 mg
EGT0001442     10 mg
EGT0001442     20 mg
EGT0001442     50 mg
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001              
_________________________________________________________________________________________  
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 95 of 100  
 
Figure 14.2. 2 Fasting Plasma Glucose in Change from Baseline (mean± SE)  - Double -blind Segment  
 
 
 
 
Note:  Baseline is defined as the mean of FPG values on day -2 and day 1. 
  
Time (Day) 2  8  15  22  29  35  43Change in Fasting Plasma Glucose (mg/dL)
-600-400-2000200Placebo
EGT0001442    5 mg
EGT0001442    10 mg
EGT0001442    20 mg
EGT0001442    50 mg
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001              
_________________________________________________________________________________________  
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 96 of 100  
Similar Figures:  
 
 
Figure 14.2. 3 Body Weight  (mean± SE)  - Double -blind Segment  
 
 
Figure 14.2. 4 Body Weight  in Change from Baseline (mean± SE)  - Double -blind Segment  
  
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001              
_________________________________________________________________________________________  
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 97 of 100  
Figure 14.2. 5 HbA1c ( mean± SE)  - Double -blind Segment   
 
 
         Predose  (Day 1)                                       Postdose  (Day 2 9) 
 
  
HbA1c (%)
02468101214 Placebo
EGT0001442    5 mg
EGT0001442    10 mg
EGT0001442    20 mg
EGT0001442    50 mg
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001              
_________________________________________________________________________________________  
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 98 of 100  
Figure 14.2. 6 24h UGE (mean± SE)  - Double -blind Segment  
 
 
 
 
         Predose  (Day 0 – Day 1)                                       Postdose  (Day 2 8 – Day 29)  
                     
  
UGE (g/day)
0102030405060708090100
Placebo
EGT0001442    5 mg
EGT0001442    10 mg
EGT0001442    20 mg
EGT0001442    50 mg
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001              
_________________________________________________________________________________________  
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 99 of 100  
Figure 14.2. 7 Mean Plasma Concentration for EGT0001442 (ng/mL)  - Dose Escalation  Segm ent  
 
 
        
 
 
 
 
 
 
Mean Graph 
Treatment: EGT0001442  5 mg
EGT0001442  10 mg
EGT0001442  20 mg
EGT0001442  50 mgConcentration (ng/mL)
0100200300400500600700800
Time (Hours)04812162024283236404448
Semi-Log Plot  
Treatment: EGT0001442  5 mg
EGT0001442  10 mg
EGT0001442  20 mg
EGT0001442  50 mgConcentration (ng/mL)
110100100010000
Time (Hours)04812162024283236404448
 
Theracos, Inc. Protocol No. THR -1442-C-402 
Cetero Research Protocol No. CTJK09001              
_________________________________________________________________________________________  
Statistical Analysis Plan Final Version 1.0 17 -May-2010                      Page 100 of 100  
 
Similar Figures:  
 
Figure 14.2. 8 Individual Plasma Concentration for EGT0001442 (ng/mL)  - Dose Escalation  Segm ent 
 